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Sailing ahead 
Joyce T.W. Cheung (Meds 2013) 
As the academic year comes to a close for many of us. we are anticipating a fresh and exc iting chapter of our li ves. I would like to congratulate the 20 13 class and use thi s platform to th ank 
them for thei r contributions to the UWOMJ throughout the years. Per-
sonally. it has been a pleasure to be a part of the UWOMJ team and the 
quality of the contributions has never ceased to amaze me. 
Our latest issue features the incredi ble genitour inary system and de-
velopment in this fi eld . It is difficult to think about th e genitourinary 
system and not have yo ur curiosity piqued by the fascinating topic of 
organ transplantati on. Within the last century. the concept of all ograft 
transplantation has evo lved fro m a procedure that was doomed to even-
tually fail to a common reali ty. due to advances in surgical technique and 
immunosuppressive med ication. Our feature article by Alex Ji ang out-
lines the latest in double-organ transplantati on of the pancreas-ki dney, 
and its therapeutic role fo r th ose suffering from di abetes and end-stage 
renal disease. Technological advancements have all owed for less in va-
sive methods of performing surgery. and Laura Callan and Nancy Chen 
outline the fie ld of surgical robot ics and give us the latest on research 
ini ti ated here at Western Un iversity. 
Behind the glamorous fa<;ade, the topic of organ transplantation is 
as complex as they come. Controversial topics range from ethical prob-
lems surrounding candidate se lecti on. to the surgical skill requi red in 
perform ing the transplantation, to medica l care afterwards to reduce the 
ri sk of organ rejecti on. To start. organs are still an extremely carce re-
source. so how do we decide on who gets to undergo thi s li fe-changing 
procedure? Kyle Luong writes about the process of kidney all ocation 
and the complex ities of choosing an appropriate candi date. The un pre-
dictable nature of having a suitable donor organ has led to the business 
of transplant touri sm. whi ch is introduced to us in thi s issue by Saad 
Ahmed. For those that are left on th e waiting list, long-term hemodialy-
sis is a life-sustaining treatment. Justine Denomme and Wendy Cui out-
line the barri ers to access ing hemodialysis, from its introducti on to the 
current state of the system. Our featured clinician. Dr. Fa isal Rehman. is 
no stranger to the world of renal di sease and its treatment. In our inter-
view with Dr. Rehm an. he speaks about hi s vision for the future of renal 
medicine and recall s a case that reminded him that despite our advances, 
we still have so much more to learn . 
We take a step back from the complex world of transplantati on and 
march into the front line of medi cine. In the world of primary care 
medicine, preventati ve health and prostate cancer screening has become 
a controversial issue over the years. Our editors update us on the topics 
of the role of prostate-specific antigen and the di gital rectal examination 
in prostate cancer screening. From the simple urinary tract infection to 
li fe-threatening urosepsis, Anthony Chow and Elaine Tang teach us how 
to approach feve r and incontinence in the emergency department. 
EDITORIAL 
All in all , we have prepared an exci ting i ue that covers complex 
tertiary care topics and also important prim ary care and preventati ve 
hea lth issues related to genitourinary med icine. Congratul ati ons to our 
contr ib utors and rev iewers for a fa ntastic year, and a big th ank yo u to 
our readers for your continued support' 
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FEATURE ARTICLE 
Simultaneous pancreas-kidney transplantation: the 
role in the treatment of type 1 diabetes and end-
stage renal disease 
Alex Jiang (Meds 2015), BHSc 
Faculty Reviewer: Dr. Patrick Luke, MD, FRCSC (Division of Urology, Department of Surgery) 
BACKG ROUND 
Type I diabetes mellitu (OM) i one of the most common chronic diseases of childhood caused by in s ~! in defic iency secondary to autoimmune destructiOn of pancreatiC beta-ce ll s. The condttton 
affects approx imately 1.4 million indi viduals in United States with an 
annual incidence of 17 cases per 100000 children.1 Unmanaged. it can 
lead to severe long-tenn compl icati ons. These include microva cular 
events. such as retinopathy. neuropathy. and nephropathy. and macro-
vascular diseases invo lving cerebrovascu lar. coronary or peripheral vas-
cular systemsn These complications are large ly attributed to hypergly-
cemia resulting from poor insulin secretion. Consequently. th e mortality 
rate for type I OM is high- 13% after 20 years of disease' 
One of the most signification complications of type I OM is end-
stage renal disease (ESRD).' It initially manifests as microalbuminuria 
with subsequent progression to proteinuria. Without intervention. 80% 
of these ca es lead to nephropathy and ultimately. ESRD (glomeru lar fil-
tration rate < 15 mL/min/ 1.73 m1) . Eligible patients with ESRD require 
dialysis or renal transplantati on for long-term management." 
The Diabetes Control and Complication Trial (DCCT) demonstrated 
that ti ght glycemic control. achieved through intensive insulin therapy. 
slows the progression and red uces the ri sk of developing micro- and 
macro-vascular complications. 7 Despite use of insulin pumps and inten-
sive insul in th erapy. no exogenous deli very of insulin has been ab le to 
sustain normoglycemia as effecti ve ly as a functi onal pancreas. A s such. 
allogeneic pancreas transplantation was developed to achieve norm a-
glycemia and insulin independeru;e. The combinati on of pancreas and 
kidney transplantati on can render a pati ent free of both insulin and di-
alysis with prevention of further diabetic comp lica ti ons, and occasional 
reversal of estab li shed disease.' 
PANCREAS TRA SPLA TATIO HISTORY 
The first pancreas transplantati on (PT) was performed in 1966 by Wil-
liam Kelly and Richard Lill ehei at the University of Minnesota in con-
junction with a kidney tran plant to treat a di abeti c uremic pati ent. '> Earl y 
procedures were as ociated with significant morbidity and mortality and 
performed in low numbers in very elect patients. With the advent of 
cyc losporine and improvements in surgical techniques, one year graft 
survi val rates exceeded 70% in 1980s.1"To date. more than 32000 cases 
ha ve been performed worldwide with ever improv ing outcomes. 11 
Currently, there are three methods of solid organ pancreas transplan-
tation. The maj ori ty (83%) of procedures are perform ed in the context 
of simultaneous pancreas-kidney (SPK) transplantation where the pan-
creas is transplanted at the same time as the k idney. The second meth od 
is pancreas aft er kidney (PA K) transplantation ( 12%) where a pancreas 
is transplanted to a pati ent who prev iously received k idney transplanta-
tion . The third method is pancreas transplant alone (PTA) (5%). which 
in vo lves transplantation of a solitary pancreas to a diabetic patient with 
norm al renal functi on. This is perfonned to counteract life-threatening 
hypoglycem ic unawareness or rapidl y progres ive diabetic complica-
ti ons refractof) to intensive insulin therapy.11 
SELECTION PROCESS 
The SPK procedure is usual!) reserved for a patient with type I OM as 
confirmed by IO\\ or absent leve l of C-peptide. 13 Candidates may also 
have signi fican t nephropath) or E RD. along with complications such 
as hypogl ycem ic unawareness. recurrent hospitali zation from diabetic 
ketoacidosis. progress ive retin opathy. enteropathy and neuropathy." 
SU RG ICALPROCED RE 
The techniques used for SPK transplantati on are diverse and institution-
dependent. Most tran splant centers use the intraperitoneal approach for 
graft placement. The pancreas is transplanted to a heterotopic location. 
usually the ri ght iliac fossa. \\ hile the kidney is transplanted to the con-
tralatera l iliac fo sa. This approach results in fewer peripancreatic fluid 
co llections and wound complicat ions. A n alternati ve approach involves 
extraperitoneal and ipsilateral placement of both grafts.15 
A rteri al anastomo is ma) be perfonned by conjoining th e donor su-
perior mesenteric artef)' and splenic artery to a Y graft of the recipient 
external or common iliac artery. The donor portal vein is anastomosed 
to th e external ili ac vein i f s) stemic drainage is provided. An alternative 
approach is anastomosis of donor porta l ve in to superior mesenteric vein 
if portal venous drainage is ava ilable. 16 A lthough thi s was performed to 
reduce lipid dysrcgu lation and rej ection rates. contemporaty studies 
have shown vel)' little di!Terences in overall long-term outcome be-
tween systemic and portal drainages.17 
OUTCOMES 
Survival 
It is believed that the PK procedure prolongs patient survival beyond 
the urvival advantage associated with renal transplantation alone. The 
5- and I 0-ycar patient surviva l rates for PK transplantation is 87% and 
70°o. respecti ve ly.wfhi s is significantly better than the surv ival rates for 
type I diabetics rece iving maintenance dia lysis and who are on trans-
plant wa iting li st. 19 l-l owever, due to inherent biases in li sting candidates 
for transplants. and the differences in donor age between PK and soli-
tary kidney (SK) transplant cohorts. the true survival benefit conferred 
by th e pancrea is unknown. 
Graft surviva l rates are excellent. The pancreatic allograft survival 
rate is 86% at one year and 53 % at I 0 years w hile kidney urvival rate 
is >95% at one year and 60% at I 0 years. 1R·211 The lower one year graft 
survi val rates for the pancreas are secondary to early transplant compli-
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cati on , including thrombosis. pancreatic fistula. and infection.l'.l" 
Quality of Life 
Pancreas transp lantati on can improve quality of life (QOL) by eliminat-
mg dmb_etes associated complications, including hypo/hyperglycemia, 
metaboltc derangements. insulin dependence, glucose monitoring and 
dtetary rest_rictions. 21 . mith et al. compared pre- and post-transplant 
<?0~2 and tound tgntficant improvement follow ing PK transplanta-ti on. F-36 Mental omponent Sum mar) scores were signifi cantly 
higher 2 years post-transplant compared to pre-tran plant (5 1.8 v . 
46.8). Similar results were obtained from the Physica l Component urn-
mary (PCS) score (48.1 vs. 40.6)n 
Glycemic Control 
T he vast majori ty of patients ach ieve complete insulin independence 
over the hort and long-tem1 following solid-organ pancreas transplant. 
In fac t. g lycem ic control is far superi or to th at achieved by insulin 
pu~p or islet-ce ll transplantsn Mora et al. demonstrated that rec ipients 
acht_eved long-term normoglycemic state following SPK transplantN 
Dunng the 15 year fo llow-up. HbA I c leve l remained wi thin normal 
range w ith no significant difference bet\\een the first and the Ia t year 
of follo~\-up (4.68% vs. 4.76%. p>0.05)Y Fasting g luco e level al o 
remained stab le during the same period (3 .94 vs. 4.38 mmol/1, p>0.05)N 
However, oral glucose to lerance test (OGTT) demonstrated decreased 
pancreatic re ponse. indicating certain deteriorati on in the functional ca-
pability of the allograft over the long-term H Whether thi s is the effect 
of immunosuppressive medications (i .e. tacrolimus. sirolimus and pred-
nisone) on islet-cell function. insulin res istance. immune-related chronic 
changes. or a combinati on thereof, is unknown. 
1 'ascular 
The pancreas transplant doe not reverse establ ished macrovascular dis-
ease in recipients. Instead. it is believed to slow down the progression 
of disease in thi high-risk popu lation. Nevertheless, fi ve years after 
transplantation. the prevalence of cerebrovascular disease (CVD), coro-
nary heart disease (C HD) and peripheral vascular di ease (PVD) is sti ll 
33%. 41% and 41 %, respective ly. Ten year after transp lantations, the 
ri sk increased only lightly to 4 I%. 50% and 50 %, respecti ve lyY Using 
peripheral thermography studi e , it is be lieved that microva cu lar perfu-
sion is improved post-pancreas transplan t as a result of better glycemic 
control 26 
Ne uropathy 
Previous studies demonstrated a benefit of SPK transp lant for diabetic 
polyneuropathy. Kenedy et al. analyzed the effect of pancreas tran plan-
tation on peripheral motor, sensory and autonomic nerve function based 
on indexes of nerve conduction ve loc ity and musc le acti on potentiaiY 
After I 2 months of follow-up. they found a ignificant improvement 
in motor and sensory indices. Thi s i supported by Martinenghi et al. , 
\\ hich demonstrated that a sustained norm og lycemic tate can amel io-
rate nerve fun cti on even if polyneuropathy is advanced1 8 
Tab le I : Selection Criteria for SPK Transplantation 13 
Confirmed diabetic nephropathy on insulin 
Presence of other secondary diabetic comp l ications 
A bil ity to endure surgery and immunosuppression 
History of compliance to medical recommendation s and therapi es 
Understanding of potential morbidity and mortality 
Creatinine clearance < 15 ml/min or on dialysis 
FEATURE ARTICLE 
Nephropathy 
M ost patients with type I DM and ESRD receive SPK to improve their 
rena l function. Fioretto et al. reported that I 0 years of sustained norma-
glycemia post-transplant reversed features of diabetic nephropathy. 2~ It 
signifi cantl y improved g lomeru lar and tubu lar lesions. and reduced the 
thickness of glomerular basement membrane and mesangia l matrix. A 
decrea e in urinary albumin excretion rate was also ob erved (20 mg/ 
day vs. I 03 mg/day ) high lighting improvement in renal fu nct ion. Ho~\ ­
ever, improvements in diabetic nephropathy post-tran splant need to be 
balanced w ith nephrotox icity incurred by the use of immuno uppress ive 
agents such as tacrolimus and cyclosporine3 " 
Retinopathy 
Diabetic retinopathy (DR) is the most common microvascu lar com pli ca-
ti on of diabetes. Several studies have reported conflict ing result about 
the effects ofSPK on retinopathy. However. most recent studies indicate 
that SPK, w ith subsequent normali zation of blood g lucose leve l. can 
improve or norm ali ze ret inal lesions31 Fo llowing SPK transplantation. 
14% of non-blind eyes howed improvement. 76% rema ined stable and 
only I 0% progressed further32 A separate study reported an improve-
ment in post-transplant vi ual acui ty in 32% of the eyes and frequency/ 
severity of vitreous hemorrhages in 46% of eyes31 It may take up to 4 
years before noti ceable functional improvement in reti nopathy and acu-
ity may be observed. Pancreas transplantati on. however. cannot reverse 
establi shed visual loss. 
CONCLUSION 
SPK transplantation is the most effecti ve treatm ent for patients " ith type 
I DM and ES RD. It addresses renal fai lure and provides phy iological 
means of attaining stable insulin secreti on. A lthough it invo lves major 
surgery and is not without ri sks, it nonetheless increases pati ent survival. 
enhances QOL and prevent progression of diabetic comp li ca tions. A s 
such. they should be considered in all eligible patients. 
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Membranoproli fe rati ve glomerul onephriti s (MPGN) is an immune-mediated di sease process, underlying I 0%-20% of nephrotic syndrome cases in children and young adults.' The 
Type I subtype (C lass ical MPGN) is the most common Hepatiti s C Vi -
rus (HCV)-as oc iated nephropathy. 2 Still. though all MPGN subtypes 
(1,11.111 ) can slowly progress to end-stage renal di sease (ERDS).3 the 
condi tion is uncommon enough to account fo r just 2.8% and 3.3% of all 
cases in ped iatr ic dialysis patients and pediatric renal transplant recipi-
ents. respectively.' This may ex plai n. in part. why studies on the effica-
cies of vari ous immunosuppressive agents in thi s conditi on are. on the 
whole, relatively limited. 
evertheless, the general fi ndings (w ith exceptions) appear to indi-
cate these agents are either ineffective or min imally effecti ve in MPGN 
(depend ing on the subtype). In the current model of evidence-based 
medicine (EBM). it is understandable that much of clinical practi ce and 
research be guided by empirical findin gs. Nonetheless. when examin-
ing the theoretica l pathogenesis of MPGN along with what is known 
of the mechanisms of action of these agents. it retrospecti ve ly becomes 
clear that some of these agents were unlikely to be effecti ve in the fi rst 
place. Thi s is not to say that theoretical understanding should be trusted 
without empiri cal veri fica tion. However. in the same way that a clinician 
should consider what is kn own about an indi vidual pati ent and order 
tests accordingly, it behooves the in vestigator to consider what is known 
about a condition before conducting an empiri cal study. 
In this review, we di scuss the underlying pathogeneni c mechani sms 
of MPGN and rev iew currently available treatm ent. We focus on idio-
pathic MPGN, as most cases of MPGN in adults have secondary causes 
(e.g. cancer. hepatiti s C) and treatment would accordingly target those 
underlying conditi ons. 
PAT HOGEN IC MECHAN ISMS 
The complement cascade consists of a seri es of proteo lytic steps cat-
alyzed by the products of prev ious steps in the eri es.R Figure I is a 
di agrammatic representati on of the complement cascade. which can be 
acti vated via more than one pathway: the two most relevant to the di s-
cuss ion being the so-called ·c lassical' and ·alternati ve ' pathways. 
The class ical path way is part of the arsenal of the adapti ve immune 
system's humoral arm. B The alternative pathway, on the other hand. is 
a part of non-specifi c or ' innate' immun ity, and does not require anti-
bodies, like the classical pathway does.8 However. after the cleavage 
of CS to CSa and C5b, classical and alternati ve pathways converge to a 
common molecular sequence.R It is at this stage, the so-called ' terminal' 
path way that over-acti vati on seems most hi ghly assoc iated with MPGN 
111.39. 10 With thi s in mind, we may classify the subtypes of MPGN as 
follows: 
Type I -Ev idence of act ivati on of th e class ical and alternati ve com-
plement path ways. ex hibiting on imm unohi stochemi stry glomerul ar de-
posits of immunoglobulin (indicating immune complex deposition as a 
contri butor to the di sease process). as we ll as components unique to the 
class ical complement cascade (C I q. C4) in add it ion to those common to 
both the classical and altern ati ve pathways (C3 ). 1 
Type II - Also known as ·Dense Deposit Disease: with conspicu-
ous absence of components unique to th e class ical compliment cascade 
(C iq. C4) vis-a-vis absence of immunoglobulin deposition. whil e still 
maintaining ev idence of C3 depositi on in the kidney( s).1 The implica-
tion is a ' pure· alternati ve path way component and a theoreti cal absence 
of an adapti ve immunity contribut ion. 
Type Il l - Less easil y classifi ed and arguably the rarest of the three 
commonly acknowledged subtypes. It is often considered a vari ation of 
Type I. It di spl ays ev idence of poss ible immune complex depos ition as a 
mediator of glomerul ar damage via the observation of immunoglobulins 
on immunohi stochemistry. but, as mentioned previously. is also hi ghly 
associated with over acti vati on of the terminal path way of the comple-
ment cascade. 
While th e pathogenesis of MPGN is now becoming clearer, it is in-
teresting to realize that currently employed therapeuti c agents do not 
necessarily target components of the di sease mechani sms. 
~ 9 I Ahem aUve Pathway I I Classical Pathway I I Lectin Pathway I 
Binding of f3~ ~ ~ complement proteins to microbial cell annose Mannose surface or G antibody 
antibody . <:> t C1 binding 
'f 
{~ protein 
~ ~~r ~ Formation ,.rtase of C3 convertase 
• convertase 
t~ al~D<:>~ convertase ·. · Cleavage !) -~~~DC~ of C3 (J~~ c, • D() 
to t \ • 
Covalent ~ ~ ~ binding of C3bto microbial surface I cs I 
convertase I cs cs convertase convertase 
Figure I. The complement cascade" 
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CORTICOSTEROIDS 
An important tudy to consider in detai l is a report of the International 
Study of Kidney Di ease in Children. '' This study showed a stati stically 
significant decrease in treatment fai lure for children with MPGN I and 
Ill. meeting their inclusion criteria when treated with prednisone rather 
than placebo (p = 0.028). However. results were not stati stically sig-
nificant for chi ldren with MPGN II included in the study, though it was 
underpowered in thi s regard. Th is was corroborated by Donadi o and Of-
ford, 12 whose study also failed to show benefi t in adult MPGN II pati ents 
comparing predni sone to placebo. Finally, though not quite reaching sta-
ti stical signifi cance (p = 0.07). there was a trend toward stab le, improved 
renal fun cti on considering all participants with MPG I. II and Ill at 
130 months of foll ow-up.' ' A 11 eak.ness of this study is that it did not 
diA'erentiate betwee n MPG I and MPG Ill under th e assumption that 
MPGN Ill was a subcategory ofM PGN I. Potential differences between 
these two groups 11ere eva luated in a retrospective study by Braun et. 
al '3 that showed statistically significant differences between a number 
of characteri stics between MPG I and MPGN Ill pati ents treated with 
pred ni sone at 3 years of follow up. Patients with MPGN I, compared 
with those having MPGN Ill. ~ere found to have more stabl e GF R's, 
lower rates of persistent hypocom plimentemia (C3). and lower rate of 
persistent hematuria and proteinuria. to name a few. 
Thus. with what evidence there is. a possibl e theoretica l simplifica-
tion is as follows wi th respect to the effect iveness of stero ids in MPG 
MPGN I - Effec ti ve 
MPG Ill - Less Effecti ve 
MPGN ll - ot Effecti ve 
The effects of steroids are so categorically broad that any ex planati on 
on a mechani stic basis of these categories would amount to specul at ion. 
More simply put, it is diffi cult to identify differences in similar di sease 
entities based on responses to a drug with broad effects. Other agents 
with greater specifi city allow us to better di stinguish such differences 
on the bas is of theoreti cal knowledge. This is illustrated nex t, by the ad-
mittedl y limited number of stud ies performed on calcineurin inhibitors. 
CALCI EURIN INHIBITORS 
Calcineurin med iates the acti vation of nuclear factor of ac ti va ted t-cells 
(NFAT). a transcripti on factor encoding a number of genes including 
I L-2 .~ IL-2 is necessary forT-ce ll proliferati on." Other gene , such as 
CD40L and others req uired forT-ce ll s to be able to acti vate B-ce ll s are 
also produced. Blocking calcineurin, therefore, is expected to have a 
number of effects on th e adapti ve immune system including decreased 
antibody production and dec reased T-ce ll inA amm atory mediator re-
lease. 
The possibility of using ca lcineurin inhibitors is best illu trated in 
two studies. The first, by Bagheri et. al. studied 18 patients with idio-
pathic MPGN (lMPG )15 . They showed that partial or complete remis-
sion of proteinuri a was achieved in 94% (p<O.O I) of patients, and that 
at an average follow-up of I 08 weeks. just one of those showed remis-
sion once treatm ent was di scont inued11 .Another study. by Singh et. a l. 
s imilarly showed tatistically signifi cant reductions in proteinuria in 8 
patient with MPGN treated with cyclosporine 16.However, both of these 
studies fa il ed to di stingui sh between different subtypes of MPGN. Ba-
gheri et a l. made no mention at all of different subtypes, and though 
Singh et al. disclosed that 5 of the MPGN pati ents were Type I and 3 
were Type II , the data for all these patients were ultimately combined. 
The pathogene is of MPGN l is directly linked to the classical pathway 
of compliment ac ti vation. wh ich constitutes part of adaptive immunity 
and th erefore is, in theory. potentially susceptibl e to inhibition by ca l-
cineurin inhibitors. Thi s cannot be stated with certainty based on the 
studies di scussed as they did not di ssociate the effects of calcineunn 
inhibitors on type I vs . type II. MPGN II. on th e other hand. IS lmked 
to innate immunity, and though there have been incidental case reports 
of MPGN II patients responding to cyclosporine", long-teml foll_ow-
up studies of small numbers of patients show that calcineurin Inhibitors 
have no impact on renal survival in MPGN I I patients17• Long-tenn renal 
survi val in MPGN I patients treated with cyc losporine should be further 
in vestigated. 
CONCLUSION/FUTURE DIRECTION 
While some ev idence exists th at suggests a role for other treatments, 
such as acety l ali cy li c ac id. dipyridamole, cyclophosphamide and 
Coum adin (warfarin). in MPG . it is unfortunately of poor quality 1R. 
Randomi zed controlled trials should be conducted to study these vari-
ou treatment option for MPGN. Given the general ineffectiveness of 
current MPGN treatm ent. it is imperative that future invest igat ions on 
potenti al therapeutic agents be conducted on the bas is of known patho-
genic mechani sms. 
A promi sing treatment option fo r MPG that has been elucidated 
by case reports 5-7 is Eculi zumab . Eculizumab is a monoclonal anti-
body for C5, a member of the complement cascade that form s part of 
th e MAC. Given the pathogenesis of MPGN. the use of Ecu lizumab 
makes intuiti ve sense and thus it is unfortunate that littl e is yet known 
about their effecti veness in the treatment of MPG . Insofar as C5 is 
in volved in both the classical and altemative pathways of complement 
acti vation. all three subtypes of MPG (which. somewhat simplified. 
may be characterized by di ffe rential ratios of classical:alternative path-
way acti vati on). could theoreticall) be treated with thi s medication. Fu-
ture studies should therefore investigate the potential for Eculizumab 
in treating MPGN. insofar as potentially. all three subtypes of MPGN 
could be treated with thi s agent. 
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I TRODUCTION 
Digital rectal examination (ORE) ma) be performed in order to identi fy 
rectal disease, prostate cancer. examine anal ph incter tone. or to exam-
ine female gyneco logica l structu re . Rectal examination has been de-
scri bed by conflicting opinions as both a cause of .. more harm than good .. 
and conversely as a .. crucial part of the examination [of a pati entr .u 
Despi te its man) diagnostic appli cati ons. the test is also uncomfortab le 
for some pati ents. doctors. and medica l students. This arti cle w ill focus 
on the characteristics of the test in pro tate cancer screening. and how 
the challenges of patient resistance and medical student educati on can 
be addressed. 
ROLE OF DRE IN PROSTATE CANCER SCREEN ING 
What l ies at the center of the ORE debate is its utility for identi fy ing 
and diagnosing different diseases. One application for ORE is for the 
detection of prostate cancer which is the most common cancer in men 
other non-melanoma skin cancers. It was diagnosed in 26.500 Canadi-
ans in 20 12, and resulted in 4000 death s3 However the disease is often 
indolent. and while one in seven men are diagnosed. only one in 27 men 
die from the disease.' The va lue of ORE can come into questi on because 
studies confl ict as to whether screening for pro tate cancer can lower 
morbidity' oneth eless. because of the frequency of the di sease and the 
poss ibili ty detect ing the disease when it is curable many patients and 
physicians choose to screen. 
The ORE is an inexpensive test th at invo lves asse sment of pro tate 
size. consistency, mobility. and irregu larit ies in shape. However th e size 
alone is not a useful pred ictor of prostate cancer risk and there is low 
correlation between transrectal ul trasonography (TRUS) measured pros-
tate vo lume and ORE estimated vo lume.H A dditionall y, whi le carcino-
mas are fe lts as hard irregu lar nodules similar indurati ons may also be 
cau ed by benign prostati c hypertrophy (13PI I) or ca lculi . Thi s means an 
examiner must order further tests when any indurati on is felt, and repeat 
the test regularly to detect for any changes or progression5 · ' The exam 
also requires technica l skill. Not all examiners can palpate the entire 
posteri or surface of the prostate. The abi I ity of an examiner to reach and 
examine the apex of the prostate. hal f of th e prostate. three quarter of it, 
and the entire prostate in a recent study was 93.7%. 66.3%. 23 .2% and 
3.2% for these respecti ve components of the prostate gland. 7 Evidence 
for th e importance of technical skil l in OREal o comes from studies of 
inter-examiner variation. One study compared consultant and res ident 
urologists who performed OREs to determine if prostates were suspi-
cious for cancer. The overall agreement was expressed with a kappa ta-
ti stic of 0.22, which suggests only fa ir agreement between examiners. 
However, while the kappa statistic among residents was 0.25; among 
consultants it was 0.63 which suggests a substantial level of agreement. ' 
Further research has shown th at more experi enced urologists tend to as-
sess th e size of a prostate more accurately.9 These findings upport the 
idea that technica l skill i important to success full y performing OREs. 
One means to address thi s i th rough improved educati on of medical 
trainees. a topic addressed later in th is arti cle. 
When ORE is used to screen for prostate cancer in men over 50 years 
of age. the cancer detecti on rate is 3.2% with a pos iti ve predicti ve value 
of2 1 %. The sensiti vity and spec i fi city of DRE are 21 % and 86% respec-
tively. 1" It is also recommended that ORE is performed in conjunction 
1~ ith prostate speci fic antigen (PSA) in prostate cancer screening be-
cause this improves the overall sensiti vity. Whereas the prostate cancer 
detection rate was 3.2% for digital rectal examinati on, it was 4.6% for 
PSA and 5.8% for the 2 methods combined. 11 Of note is that the detec-
ti on rates of the two tests only partially overlap. and together the two 
te ts detect more cases of prostate cancer. 
In conclusion. because the disease is relat ive ly indolent, it is rec-
ommended that an in formed dec ision is made by pati ents whether or 
not to screen for prostate cancer. Because the test is technically diffi cult 
to per form. steps should be taken to improve the education of medical 
tra inees. I f screen ing is to be performed. then regular ORE is recom-
mended to be used conjunction with PSA testing to increases the rate of 
cancer detecti on. 
PAT I ENT BA RRI ERS 
Some pati ent barr iers to the acceptance o f OREs include discomfort. 
embarrassment and men assoc iating th e exam w ith homosexuality. Fur-
th erm ore some men arc 1-1 orri ed about fee ling stimulated and having an 
unwanted and uncontrolled physica l response during a ORE. M en may 
not seek medica l attention that includes ORE until they' re no longer able 
to cope with symptoms: thi s could be due to both fear of the procedure 
or fear of discovering i ll ness. One ~~ ay to improve pati ent acceptance of 
ORE i to im prove pati ent educati on. A mple in formation on the process 
and reason for perfo rming the procedure should be provided for pati ents. 
To be included in the conver ation could be di cussion about past expe-
rience with ORE. whether positi ve or negati ve. Positioning can also 
be chosen to reduce pati ent embarrassment during the procedure. The 
left lateral position has been show to be the least embarrass ing with-
out compromising the re ults of the test. 11 Furthem1ore. many patients 
view co lonoscopy drasticall y differently than OR E. The reason is that 
co lonoscopy is often perce ived as more technol og ical and hence per-
ceived as more scientifi c. Therefore extra care should be taken by physi-
cians to maintain a professional environment during ORE. Language 
used should be chosen carefu l ly. For example, phrases li ke ' examine' 
the prostate rather than ' fee l ' the prostate make the proce s ound more 
cl in ica l and scientifi c, hence more accepted by patients who are wary of 
the procedure.13 
TEACHING OF THE DRE 
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One factor limiting the usefulness of ORE is in ter-examiner variabi lity, 
which results in inconsistent exam findings. This has promoted studies 
that examine how the digital rectal exam is taught to med ical students 
and res idents. Teaching during medical schoo l has a huge bearing on 
a physician's future kill in performing ORE, yet se veral aspects limit 
what students learn . ORE is often learned through textbook reading and 
facilitator demonstrati ons. The three dimensional nature of the prostate 
is di fficult to convey in tex tbooks. In demonstrati ons. it is challenging 
to teach th e subtleties of palpati on because ORE is a very internal pro-
cedure.1 4 
One attempt to solve thi s problem uses rectal simulators which are 
currently being developed to teach the OR E. A mannequin mode ling the 
rectum and prostate i attached to electronic sensors, so that when an 
examiner palpates the rectum sensors analyze the pressure and locati on 
of palpation for instructors to assess and give feedback . Beyond use as a 
teaching tool. thi s simulator can also detect differences in performance 
between examiners and so attempts to quanti fy inter-examiner vari abil-
ity in ORE. 
Unive rsity of Ca lifornia Medical Schoo l deve loped a ORE teaching 
model that include didacti c lectures. practical learning by performing 
the procedure on a standardized pati ent, and small group sessions led by 
fac ulty members. In a study conducted by Kaplan et. al. students· com-
fort level in terms of performing ORE were comparing bel\veen group 
of students that recei ved ORE training from the new teaching mode l and 
students that didn ' t receive formal training in performing ORE. Students 
who had received the teaching model were more comfortable perform-
ing OREs. Examiner comfort and confidence level is crucial to pati ent 
comfort and confidence; hence thi s mode l of learning through three mo-
dalities shou ld be given consideration for more widespread use in the 
teaching of medical students. 15 
CONCLUSION 
De pite differences in prostate cancer screening guidelines bel\-veen 
vari ous countries, the majori ty of countries recommend a com binati on 
approach of serum PSA with DRE. 1r' T herefore ORE is still an important 
part of undergraduate and postgraduate medical curricul a. 
Things to keep in mind: 
Reassure your patient: explain to th em why you' re doing thi s exam 
and what to expect during the exam. 
Use medical terms to describe procedure: examine. palpate, drape, 
examination table etc. 
Ask the patient if they have ever had a bad experience during a 
ORE. 
Position choice: left lateral po iti on is perceived by patients to be 
least embarrassing, while ach ieving similar results as other posi-
tions. 16 
There are limitations to use of ORE in pro tate cancer sc reening. How-
ever as a procedure that is low ri sk. fast and office sett ing procedure 
when used in combination with PSA increase cancer detection compar-
ing to PSA alone, there is still a place for ORE in medicine and prostate 
cancer screening today. There is inter-examiner vari ab ili ty meaning that 
experi ence leve l has an impact on efficacy of thi s test. Therefore ORE 
should to be more rigorously taught to new generations of phys icians 
and care should be taking regarding how ORE is taught. Modifications 
should be made to the teaching of this procedure in medical school s. 
Traditional learning from texts and demonstrations should be enhanced 
by the incorporation of modem technology like ORE simulators and 
more comprehensive teaching models to educate future phys icians. 
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Saad Ahmed (Meds 2016) 
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M ale. 45 )ears old. presenting wi th severe sepsis- rushed in straight from the airport . On fu rther in vest igati on the pati ent also has an inA amed incision lateral to their upper right ab-
dominal quadrant that seems infected. The famil) seems ti ght-lipped 
about the detai ls of the trip. but on pressing they mentioned a kidne) 
transplant done abroad as the rea on. 
What do) ou do in this situation? 
INTERNATIO ALLY: 
In 2008 delegates from all around the \\ orl d drafted the Istanbul Dec-
laration. It expl ici tl y stated that organ trafficking and commercialism 
exploits the poor and should be completely banned.' Whereas organ traf-
ficking is done with coercion and usually violence. even organ commer-
ciali sm involve a certain amount of monetary coe rcion, espec ially since 
there are power asymmetri es between someone in a deve loped country 
and a desperately poor person in a developing country.' Those who are 
forced to sell their kidne)S as a result of fi nancial hardships frequently 
report that they are left frai l and sick. with the money di sappearing in 
no time. 2 Secondly. multiple studies from Canada. th e US, and A ustralia 
have hown that the health outcome of transplants tourists are signi fi -
cantly worse than patients who rece ived their transplants domestically 
and legitimately. 
The policy makers at the Istanbul Dec larati on recognized that or-
gan traffi cking and commerciali sm is ultimately dri ven by demand from 
people in developed countries who are suffering on organ rec ipient 
waitli sts. To thi s end. they reinforced the importance of policies that 
increase dome ti c organ donati on rates.' some of which have been ad-
opted in Canada. An example of these poli cies being put into practice is 
the L iv ing Donor Paired Exchange (LOPE) Reg istry, a national registry 
for pati ents suffering from chronic k idney di ca e. and the Li ving Organ 
Donor Reimbursement Program (LODRP), which has been adopted in 
at least 5 prov inces. The LODRP reim burses organ donors for va rious 
expenses and time lost throughout the process of donati on and recovery. 
The LOPE matches transplant pati ent who have incompatible l iv ing 
donors with each other - th e idea being that one pati ent 's incompatible 
donor may be compatib le with another pati ent, who e li v ing donor may 
be compatibl e with the fo rmer pati ent. It ha been shown to incn.:asc 
organ donati on by up to I 0%.3 
The Dec laration has had signifi cant inAuence globall y - especially 
in countries formerl y considered to be hotbeds of organ traffi cking and 
commercialism, such as China. Pakistan and the Philippines. Legisla-
ti on is now in place to prohibit the practi ce.'' Countries are also working 
together to apprehend and charge those who continue to participate in 
organ traffi cking. For instance. European and Canadian authoriti es in 
Kosovo recently dismantled an infamous organ traffi cking ring spread 
out across three continents: and a crimin al trial has begun to sentence 
the traffi ckers2 
DOMESTICALLY: 
In Canada. the Canadian Society of Transplantation and the Canadian 
Society of ephrology j ointly released a policy statement on organ traf-
ficking and transplant tourism. In their preamble, the) affirmed the prin-
ciples of the I tanbul Dec laration5 and a physician ·s duty to never deny 
care to a patient. T he main crux of the policy statement is focused on 
preventing people from undergoing transplant tourism in th e first pl ace.~ 
The myri ad problems and complications of transplant tourism should be 
coherent!) communicated to patients- such as the diffi culty in receiving 
insurance coverage for long-term anti-rejecti on medicati ons due to the 
lack of documentati on and unethical nature of the transplant• To thi s 
end. the Kidney Foundati on of Canada released a set of pamphlets that 
warn people about the possible consequences of transplant tourism (see 
http: //www.kidney.ca /docu ment.doc?id-1239). 
The data from a ingle centre study which looked at 93 transplant 
tourists from British Co lumbia. affi rms the need to r thorough and proper 
pre-tran plant counseling.6 The tud) found that 30% of the re pondents 
had never been referred for a transplant consult, and had thus preemp-
ti vely undergone a kidney transplant. nother 33% of the transplant 
touri ts in the study had completed a transplant consult. and after being 
waitli sted lo r a transplant sought a commercial transplant. This speaks 
to a need for a multi-faceted policy. I f 30% of transplant tourists are 
pre-empti ve ly rece iving transplants without an actual referral after the 
development of end-stage renal disease, it speaks to a need for public 
campaigns discouraging transplant tourism. as well as a need to educate 
patients before the deve lopment of end-stage renal di sease. Secondly. 
other patients recei ved a referral. but failed to follow up and were lost to 
the system - hence the tudy mentions that pati ents must be tracked bet-
ter. Furtherm ore. considering that the vast maj ority of transplant tourists 
were ethnic minorities. j the study argued that outreach effot1s must be 
made to members of the e communiti es to discourage transplant tour-
' ~n . A nd for the 33% of _pati ents who had gone abroad to r a transplant 
alter bctng put on a wa1tlt sl , the study advocated for poli cie such as the 
Paired Li ving Donor Exchange Registry. Studies held in centres across 
the US and Australia had simi lar findings and recommendations_7.a.9 
Numerous pub lic hea lth problems have been rai sed by a anadian 
~tudy o f transplant tourists. 10 There have been cases of pati ents present-
tng wtlh multtple drug-restslant Escherichia coli, acti ve tuberculosi a 
~ve il as other viru es ~nd funga l in fecti ons not typically seen in ana,da. 
fhe pre~ence ofmu lttpl e drug resistant bacteri a certainly poses a domes-
ltc publtc hea lth concern . 
LEGALLY & SOME DEFI NITIONS: 
Under Section 279.04 or the Criminal Code of anada, it is a criminal 
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offe nce to ex plo it anothe r person a nd by the use of fo rce, decepti o n, o r 
coerc ion re move the ir organs o r ti ssues - be it domesti ca ll y o r inte m a-
tiona lly.11 · 12 The re is however c urre ntly no overa rc hing fed era l law pro -
hibiting C anadia ns from o bta ining comme rc ia l organ tra nsp lants over-
seas. whi c h were so ld by a consens ua l do no r. 13· 14 In 2009, the Ho use of 
Comm o ns nearly passed Bill C-381 into law. 15 It soug ht to expli c itl y 
pro hibit Canadi a ns fro m go ing a broad to purc hase a n o rgan and would 
have crimina li zed a ny so rt o f pa rti c ipa tio n, even indirect, in o rgan traf-
fi c king o r tra nspla nt commerc ia li sm . 
Bill C -3 8 1 would have a lso required health care pro fess io na ls to re-
port a ny pa ti e nts of the irs w ho had unde rgone tra ns pla nt to uri s m , muc h 
akin to m andatory repo rting mecha ni sms a lready in pl ace. 16 Som e aca-
de mics a rg ue that si mply ba nning thi s practice w ill no t work.4 To contro l 
a n industry tha t has been roughl y est im a ted to gene rate $600 milli o n to 
$ 1. 2 billi o n a year-3 in profits w ill be diffi c ult, especia ll y w he n a m a rke t 
of despe ra te ly ill a nd despe rate ly poor people continues to ex ist. T hey 
contend that o rgan scarc ity, w hi ch dri ves de m a nd .. need s to be dealt w ith 
by inc reasing o rgan do natio n via po li c ies suc h as offe ring incenti ve fo r 
donatio n. However. it is hard to extrapo late these acade mi cs' a rg um e nts 
furthe r, as it would o th e rw ise lead to the unjustifi a ble posi tio n o f a llow-
ing tra nspl ant to uri sm in som e s hape o r fo m1 . 
CONCLUSION: 
Fundam e nta lly. the issue o f organ transpla ntatio n a nd comme rc ia l ism is 
one o f despe rati o n-dri ven de m a nd . Phys ic ians should e ns ure tha t the ir 
pati ents unde rsta nd the severe and f req uent s ide e ffects of tra nsp lant 
to uri sm . They sho uld ex pla in the he in ous facts - the va ri o us c rimina l 
o rganizati o ns tha t the tra nspl ant trad e fund s. a nd the incredibly unethi-
cal nature of the trade, w hic h is no thing short o f th e explo ita tio n of the 
poor. T hese peril s must be communi cate d earl y. be fo re o rgan fa ilure, so 
that pa ti e nts do not act out of despe ratio n . A nd if a pati e nt w ith a com-
m erc ia l tra nspl ant comes into the ir care. they must s imply rem e mbe r 
the ir duty to minimi ze the patie nt's s uffering a nd provide the best pos-
s ibl e care for the m . 
T he stakes a re nothing m o re tha n the li ves o f th e most v ulnera ble and 
di stressed indi v idua ls in o ur communi ties a nd a ro und th e world. 
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ABSTRACT 
Lloyd Shapley and A lvin E. Roth have recently been awarded the obe l 
Prize in Econom ics for their work in match ing theory. A lthough branch-
ing from the field of economics. matching theory has had many impli-
cat ions in the world of medicine. For example. the National Residency 
Matching Program in the United States is an app lication of matching 
theory. The focus of thi s artic le is the application of matching theory 
to kidney transplant allocation. Kidn ey tran splantation is the best treat-
ment for end stage renal fai lure. Unfortunately. the demand for k idney 
exceeds supply. Kidney paired exchange programs. which have begun 
to gamer great success in increasing the number of kidney transplants 
worl dwide. base thei r fo undations on matching theory. Overviewed in 
thi s paper wi l l be how these programs were created and work. their suc-
cesses. and some of the unique challenges and logistical obstac les they 
face. 
INTRODUCTION 
Trad itionally, markets functi on wi th monetary exchange faci litating the 
movement of goods to buyers from sellers. However in some instances 
monetary exchange is unfeasible due to the nature of the market and as 
a result. prototypical market structure is inapp licable. Matching theory 
is a branch of game theory that deals with thi s non-price allocation. Pio-
neered by Lloyd Shapley in the 1950s and 1960s, it has been applied 
to real markets with great ucces . Two med ica l markets where match-
ing theory has garnered thi success are re idency matching and kid-
ney transplant allocati on whose designs owe greatly to A lvin E. Roth . 
an American economist who made great forays into the app lication of 
Shapley 's theories and their further development. Recent ly. both men 
were awarded the Nobel Prize in Economics fo r their work . In li ght of 
its contemporary step back into the pub lic eye. thi article wil l briefl y 
outline matching theory with some example from rea l markets. Finally, 
th e applicat ion of matching theory to kidney transplant allocati on wil l be 
explored, with a discuss ion of its succe s and future direction s. 
MATCH I NG THEORY: BASICS 
Shapley·s th eory is based on stable matching. In their 1962 paper. Gale 
and Shapley demonstrated thi s idea with the stab le marri age problem. 1 
The stab le marri age prob lem asked how a number of women could be 
matched to a number of men, con idering their respecti ve preferences to r 
each member of the opposite sex . They showed that no matter the prefer-
ences. there would always exist a stable allocation. A stable allocati on is 
one whereby no parties can be better off by further exchange. tabi I ity 
is desirable in thi s example and its rea l world extrapo lations as stability 
is seen as an indication of efficiency because further improvement of 
happiness from exchange is impossib le. Addi ti onally, stability imparts 
robustness to allocation systems since it eliminates incenti ves for parti es 
to disobey or manipulate the rules of the system. In the stable marriage 
prob lem. the solution was th e Gale-Shap ley .. deferred acceptance"' algo-
rithm. Suppose the men are aiiO\\ ed to propose to the women. Each man 
would propose to his favourite woman. A woman with more than one 
proposa l would keep her favourite proposal ·on hold ' without accepting. 
and rejecting all other . (Women wi th only one proposal would keep 
that propo a! on hold as well. ) With the second round of proposals. men 
who were rej ected in the preceding round would propose to their second 
ranked woman. The women behave similarly as before. keeping their 
best proposal on hold and rejecting the rest. including any proposals 
from prev ious rounds. Eventually. all women w ill have been proposed 
to at which point they are all requ ired to accept their on hold propos-
als. It was shovm that all matches made in this manner were stable. An 
im pli ca ti on of the Gale-Shaple) algorithm was that the propos ing party 
wou ld secure more favourable matches. 
MATCHING THEORY: APPLICATION 
At the crux of thi s deferred acceptance algorithm is free trading. In the 
stable marri age problem. the women were able to trade tentati ve propos-
als for anything better that came along. A lthough the marri age problem 
may seem contri ved. it indeed has real world counterparts. One such 
market is residency matching in the US. Roth demonstrated that the 
matching algorithm used by the Nati onal Resident Matching Program 
(N RMP) \\as able to make stab le matche because it was essentially an 
ada ~tall on of the Gale-Shapley algorithm . 1 The allocati on of residency 
positions was another stab le marriage problem. with the hospitals pro-
posing to the appli cants. Harkening back to the stable marri age problem. 
Roth noted th at the algorithm produced outcomes favouring hospital s. 
Moreover. With more physician couples wi hing to match to the same ar-
eas. th e algorithm was proving insuffi cient in meeting these new needs. 
In 1995, Roth and Elliot Peranson were enli sted to redesign the NRMP 
to accommodate couple matching. Their algorithm was adopted in 1997 
and used ever ince. 3 
KIDNEY TRANSPLANT 
The best treatm ent lo r end stage renal failure is kidney transplant. Pa-
ti ents rece iving transplants li ve I 0 years longer than th ose 0 d. 1 · • U r I h . n 1a ysis. 
n ortunate y. t e demand for kidneys outpaces the supply of deceased 
donors With over 
5
70% of Canad ians who are on organ waiting lists, 
needmg a k idney~ Livmg donors are another resource. prov iding > 16 
yeats of dialysis-free survival compared to the 8.6 years fronl a d d d ' u · ecease 
onor. ntortunately, the challenge with utilizing this pool of li v ing do-
~ors wa that many pairs of wi lling donors and recipients were deemed 
mcompallble after screenmg. In formation from these d 
. onor was usu-
ally not recorded for follow up and th e pair would be s t h 1 · 
. en ome. Wtth 
such congestiOn on the deceased donor waiting li st th 
. . . . • ere was an uroent 
need to better uttltze lt vmg donors. "' 
A so lution to the problem wou ld be another applicati on of Gale 
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and Shapley 's matching theory. Whereas the marri age prob lem and the 
NRMP represented a two-sided market (two parti es matching with one 
another), the kidney exchange problem is one-sided as every indi vidual 
and their initial donor candidate is regarded as a single item. Gale ·s top-
trading cyc le algorithm. which also produces stable matches. wa the an-
swer to thi s modified allocati on problem. Objects are initiall y distributed 
to each entity and like the deferred acceptance algorithm. subsequent 
trading occurs.' In kidney transplantation. the initial allocation of ob-
jects is analogous to the pairs of incompatibl e donors and their intended 
rectptents. ow, imagine two incompatible pairs of a donor and rec ipi -
ent. I f each donor happened to be a match for the rec ipient in the other 
pair. a mutually beneficial exchange would be poss ible whereby both 
patients receive a compatibl e donor. T his system of exchanges has been 
dubbed Kidney Paired Exchange (KPE). Exchanges could and have be-
come more com pi icated. with further pairs participating in a daisy chain 
of trades. KPE has also been adapted to make use of the growing number 
of altruisti c or non-directed donors. 9 In domino-paired donation, the al-
trui stic donor donates the kidney to a recipient or an incompatibl e pair. 
The donor of said pair wou ld then donate th eir kidney to a compatibl e 
rec ipient on the waitli st. Longer domino chains have been accomplished, 
with the longest to date spanning 30 kidneys and 60 indi viduals. 'u 
SUCCESS 
Since it was first suggested by Rapaport in 1986. 11 several inform al ex-
changes have been reported . 12 Not until 2005 was the first nati onal KPE 
program establi shed in the Netherl ands. 13 In the US. Roth helped design 
the New England Program for Kidney Exchange, 14 and along w ith the 
Ohio program was one of the early preludes to the national program 
propo ed by UNOS in 20 10. In Canada. a three prov ince pilot program 
initiated in 2009 and has become nationwide as of October 20 I 0. ,; The 
American programs have seen increased numbers of kidney exchanges 
in each subsequent year with > 1000 cumulati ve transplants since 1998. 
11 Researchers suggest that optimal utilizati on of the program could see 
as many as I 000-2000 additional transplants per year in the US; 16 av-
ing the country $750 million USD in dialys i costs annually. 17 With the 
Canad ian program still in its infancy. there is insufficient data to evalu-
ate its success. To date. the Canadian L iving Paired Donor Exchange 
Registry has facilitated 144 transplants w ith 14 more scheduled before 
the end of the year. Increased transplants mean more patients are ex-
periencing a lessened burden of dialysis. better mortality. and a higher 
quality of li fe. 'R 
CHALLENGES AND FUTURE DIRECTIONS 
KPE program implementation elicits vari ous challenges. One impli ca-
tion that arose was that all transplants wou ld have to be done simultane-
ously to prevent donor reneg ing. Only recentl y have non- imultaneous 
donations been performed with altrui sti c donors being incorporated into 
non-simultaneous extended altruisti c donor (NEAD) chains. NEAD 
resembles domino-paired exchange except the last donor in the chain 
does not donate to a waiting li st recipient. but rather becomes a bridge 
donor. awaiting more pairs. Optimisti cally, th e potential for extending 
the wave of exchanges outweighs the risk of donor reneging. Some ar-
gue however, to not be overconfident because of the honeymoon phase 
where a single donor is able to initiate a large chain of donations. Many 
chains wi ll not propagate indefinitely and bridge donors accumulate as 
matches become rarer. M any drop out after some period of time. 19 A 
national KPE exchange also presents the need for co-ordination between 
the various transplant centers and a centrali zed registry. It is no surpri se 
that additional viable exchanges are easier to find with a larger pool 
of pairs. However, there needs to be incentives for hospitals to enroll 
donor-recipient pairs instead of performing short chain exchanges in-
ternally. As well , the transport of donors across the country presents an-
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other challenge both log isti ca ll y and financially. These are all issues th at 
need to be addressed i f KPE is to be used to its full potential. 
CONCLUSION 
This article has prov ided an introducti on to matching theory and the 
ways it has been applied in rea l markets. w ith special regard to kidney 
transplant allocati on. The discussion of KPE's permutat ions. success-
es and shortcomings here are definitely not exhausti ve. For instance. 
the ethical issues associated with KPE have not been addressed here. 
Further reading is encouraged for those interested. U ltimately. match-
ing theory proves to be applicab le in many contexts. and has especially 
found some utility in the fi eld of kidney transplantati on. 
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HEALTH POLICY AND ECONOMICS Rewa rding Physic ian 
Job Opportunities 
in South East 
Saskatchewan. 
Dec: ll ( l 2):2778-2779. 
Sun Country 
HEALTH REGION 
Sun Country Health Region is currently recruiting for General Practice 
Physicians, General Practice/Surgeon, and a Regional Locum. Each 
opportunity has strong and established earnings potential and each 
opportunity partners with other physicians. If you are eligible for 
registration with the College of Physicians and Surgeons of 
Saskatchewan we are interested in you! 
Sun Country Health Region (SCHR) covers the southeast portion of 
Saskatchewan Canada, from the Manitoba border to the U.S. border, 
encompassing serene prairie and parkland . SCHR provides health care 
services to the population of 54 ,000 residing in the region. 
See www.suncountry.sk.ca for a 
complete listing of physician job 
opportunities. 
Contact the Recruitment Team: 
Phone: 306-842-8320 
Toll Free: 1-866-578-7247 
jobs@schr.sk.ca 
- .suncountry.sk.ca 
Bluewater Health 
Sarnia & Petrolia, Ontario 
Bluewater Health is recruiting for the following positions to provide services to the residents of 
Sarnia-Lambton both in the community and at the hospital. 
• Dermatologist • Neurologist 
• Paediatrician • Psychiatrist 
• Rheumatologist • Emergency Physicians 
• Hospitalists • Family Physicians (Petrolia)- including low acuity Emergency 
Bluewater Health is a 320 bed hospital operating on 2 sites which includes a recently completed 
$319 million redevelopment. The hospital offers excellent medical and diagnostic supports : 
• A broad range of diagnostic services, including CT and MRI. 
• Full spectrum of specialists available 24/7 (neurosurgery not available) 
Sarnia was rated the Most Livable City in Ontario by the Pembina Institute (August 2007). Situated on the 
shores of Lake Huron at the border to Michigan, Sarnia offers excellent quality 
of life, sports, arts and culture, education, state of the art health care, 
and beautiful natural environment 
To inquire about these positions, please contact: 
Dr. Mark Taylor, Chief of Professional Staff 
Bluewater Health 
Medica I_ affairs@bluewaterhea lth . ca 
519-464-4400 ext 4534. 
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The role of prostate-specific antigen (PSA) testing 
in screening for prostate cancer 
Charlotte Hunter (Meds 2015) and Paul Zamiara (Meds 2016) 
Faculty Reviewer: Dr. D. Scott Ernst, MD, FRCPC (Department of Oncology, Division of Medical Oncology) 
Prostate spec ifi c ant igen (PSA) is a serine protease expressed mainly by th e prostate gland and detectab le in normal, benign hy-pertrophic. and neoplastic prostate ti ue. Whi le the majority of 
the PSA produced by the prostate gland is released into emen, a small 
amount (approximately one million-fold lower) normally leaks into the 
circulati on and is detectable by immunoa a) . In the hyper- and neoplas-
tic prostate, though. its secreti on into prostate ducts is lost and conse-
quently more PSA is released into extrace llular fluid and the circulati on.1 
Serum PSA levels can therefore be used to track the growth or shrinkage 
of prostate tumors: indeed. the FDA approved it u e to monitor cancer 
progres ion (i.e. tumor growth. response to treatment. recurrence) in al-
ready diagnosed men in 1986.1 
PSA became the first biomarker (indicator of biological state) ap-
proved for screening asymptomati c men for cancer in 1994, when the 
FDA approved its use in conjunction with the digital rectal exam (ORE) 
to screen for prostate cancer. A PSA level of 4.0 ~g/L was traditionally 
con idered the upper limit of norm al. and a prostate biopsy was rec-
ommended to patients exceed ing this level. However. prostate cancer 
screening based on PSA level has limited specificity (33%. versus 86% 
sensiti vity3). as inflammation (prostatitis) and benign growth (benign 
prostatic hyperplasia) of the prostate will also elevate PSA leve ls.2 
Therefore, despite the PSA test ·s utility in monitoring tumor progre -
sion and response to treatment, its u e as a creen ing test for prostate 
cancer in asymptomatic men remains controversial. Because of the con-
siderable publi c health burden imposed by prostate cancer - it was the 
most diagnosed cancer in males in 2008 (about 899 000 cases and 258 
000 deaths worldwide). w ith 72% of cases occurring in developed coun-
tries' - proper screening too ls and guidelines are extremely important. 
The Canadian Cancer Society has suggested that th e benefits of hav-
ing a PSA test for screening purposes include the peace of mind granted 
by a normal result: identifi cation of those in need of further testing ( if 
the result is higher than expected for the patient" age): and the ability 
to detect prostate cancer before it is symptomati c and/or before it has 
spread beyond the prostate. ' However, they also point out the potential 
for harm as ociated with prostate cance r screening. such as the unneces-
sary anxiety cau ed by a fal se positi ve: the potential for a fal se negative 
and the propensity to then ignore worri some symptoms that may emerge 
later: and the ri sks associated with treatment of slow growing prostate 
cancer that could have been left alone. 
The current guidelines for prostate cancer screen ing in Ontario state 
that PSA te ting should not be used as a population-wide screen ing too l 
for early detection of prostate cancer in asymptomatic men.6 Instead, 
physician should discuss the benefits and potential harms of testing 
w ith men who are between the ages of 50 and 75 and have a life expec-
tancy of at least I 0 years. This discuss ion should also include men over 
40 with a first degree relati ve who has had prostate cancer. and men of 
African ancestry. With this inform ation. men can th en decide for them-
sel ve whether they would like to undergo testing. A PSA va lue >4.0 
~tg/L or an abnormal OR E \varrants further investigati on. 
Dr. George Kim (personal communicati on. December 4. 20 12). a 
famil y phys ician working in outh western Ontari o. restri cts his ordering 
of PSA tests to symptomatic men. In th e event of a 11 0rri some change in 
prostate-related symptoms (i.e. increased urinal") urgency or frequency. 
or poor urinary stream 11 ith urinal")' tract infection unlike!). e pecially 
when the patient is of African descent or has a first degree relative diag-
nosed with prostate cancer prior to age 65 ). he prefers to send patients 
for prostate ultrasound and possible biopsy. However. Dr. Kim finds the 
PSA test to be a convenient test in the interim i f the ultrasound cannot 
take place within 10 days. In term s of screening. Dr. Kim be l ieves pa-
tients would like to undergo a simple test, l ike the PSA test that could 
defi nitively detect cancer: because of this desire for certainty. patients 
may have unrealistic expectati ons regarding the validity of test results. 
He th erefore recommends di cu sing with patients the advantages and 
limitati ons of PSA testing (including its low pecificity). and exp laining 
why it cannot replace other surveillance methods (i.e. the ORE). 
Tak ing a more extreme stance than the Ontario guidelines. the .S. 
Preventi ve ervices Task Force recent!) recommended agai nst any 
PSA-based screening for prostate cancer. regardl ess of age. based on 
their conclusion that many men are harmed by thi s screening test and 
few benefit from it7 The Task Force· conclu ions were largely based 
upon two ongoing studi es: the U.S. Prostate. Lung. Co lorectal & Ovari-
an Cancer (PLCO) Screening Tria l and the European Randomi zed tudy 
of Screening for Prostate Cancer (ERSPC). 
The PLCO trial in vo lved 76 693 men bet11 een the ages of 55 and 74 
who were randomi zed to annual P A screening for 6 year . combined 
wi th a ORE for 4 years. or care as usual.x A PSA va lue >4.0 ~g/L was 
used as the cutoA· for a positi ve screen resu lt. The incidence of prostate 
cancer was signifi cantly higher in the screening group after 7 years of 
fo llow-up (RR. 1.22 [95% CL 1.16-1.29]). but there was no signifi cant 
di lference in prostate cancer mortality (RR. 1.1 3 [95% CL 0. 75-1. 70)) . 
The I 0 year follow-up data. wh ile only 67% complete. was also consi -
tent w ith these findings. 
The ERSPC trial randomized 182.000 men bet11een the age of 50 
and 74 to either the screening group. which received a PSA test ever)' 
2-7 years (depend ing on the centre). or the control group, which re-
ceived care as usual. '1 Most centres in the tri al used a PSA cutoff value of 
3 ~g/L, with a positi ve screen result 1·\ arranting a biopsy. After a median 
follow-up of 9 years. there was no stati sti ca lly significant difference in 
prostate cancer mortality bet11 een the men ass igned to the screening 
group and the controls (RR. 0.85 [95% CL 0. 73~1.00]) . However. in ; 
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prespecifi ed subgroup of 162 243 men aged 55 to 69 there was a sig-
nifi cant abso lute ri sk reduction in prostate cancer mortality for the men 
assigned to screening (RR. 0.80 [95% Cl, 0.65-0.98]). 
Beyond the fact that th e resul ts of these t11 0 tri als do not prov ide u 
with a consi tent answer to the questi on of whether PSA-based screen-
ing reduces prostate cancer mortali ty, the U.S. Preventi ve Services Task 
Force was somewh at critical of the methods used in these trials. Both tri-
als failed to exclude men who had had previou P A testing, the PLCO 
tri al had substantial contamination of the control group (up to 52% of 
controls received a PSA test duri ng the trial). and the ERSPC trial used 
a range of PSA cut-off points (>2.5 to 4 11g/L) and screening intervals 
depending on the centre."' 
The Task Force ·s dec ision-making was also influenced by harms as-
sociated with PSA-based creening. For exampl e. 75.9% of men who 
underwe nt a bi opS) because of an elevated PSA va lue in the ERPSC 
tri al had received fa l e-pos iti ve re ult .9 Complicati on of di agnosti c 
eva luations occurred in 68 of I 0 000 procedures in the PLCO trial. and 
in cluded bl eeding. in fec tions. and urinary diffi cul ty' 
Given the uncertainty surrounding the interim results of these two 
major tri als. it will be important to see whether longer-term foll ow-
up of the study part icipants conveys a clearer message about whether 
PSA-based screenin g red uce morta lity. Even with the current evidence, 
the Task Force's strict recomm endation aga inst any PSA testing for 
creening purposes has been criticized for preventing patients from be-
ing in vo lved in decision-making." In a ew England Journal of Medi-
cine commentary written in response to the Task Force's report, Drs. 
McNaughton-Collins and Barry (two prostate cancer speciali sts affi li-
ated with Harvard Medi cal School and Massachusetts General Hospital) 
argued for a strategy similar to Ontari o's guidelines in which patients 
are made aware of the benefit s and harms assoc iated with PSA-based 
screening and are able to dec ide for themselves whether the potenti all y 
small benefit is worth it to th em. " However. they al so suggested that if 
physicians continue to order PSA tests for screening purposes they must 
do a better job of emphasizing the potenti al harm assoc iated with PSA 
testing. rather than touting only the benefits of screening. Physicians 
must also make sure that th ey are not overtreating pati ents who might 
benefit more from a "watchful wa iting" approach. 
Thus fa r. measurement of abso lute PSA level for the purposes of 
prostate cancer monitoring and screening have been disc ussed. There 
are other measurements to increase screening specifi city that are cur-
rently being ex pl ored. A recent retrospecti ve cohort study eva luated the 
utility or a measure ca lled the PSA ve loc ity (P AV) ri sk count in 18 214 
men enrolled in a prostate cancer screening study. 12 PSAV refers to the 
yearly change in PSA units, and th e ri sk count is a mea ure of the num-
ber of times PSAV exceeds 0.4 11 g/L. A PSAV ri sk count :::: 2 (i. e. two 
consecuti ve yearly increases in PSA leve ls exceeding 0.4 11g/L) showed 
96% specificity (compared to the reported 33% specifi city for the abso-
lute PSA leveJ3) and was associated with a signifi cantly in creased ri sk 
of prostate cancer (O R 8.2 [95% Cl. 7.0-9.6]) . In thi s study. the odds 
ratio for prostate cancer determined by PSA level. in contrast. was only 
1.25 (95% Cl. 1.22-1 .28). These results suggest that furth er in vestiga-
tion or PSAV utility in prostate cancer screening is warranted.12 The US 
Nati onal Cancer Institute al so li sts PSA density of the transition zone 
(PSA leve l di vided by the vo lume or the prostate 's transiti on zone) and 
age-specifi c PSA reference ranges as parameters under in vestiga ti on 
for improvement of PSA screening spec ificity.2 While these alternati ve 
screening option are being in vesti gated, Ontari o's recommend ation that 
patients hould be properly informed about PSA testing and encouraged 
to participate in deci sion-making seems appropri ate. 
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I NT ROD UCTION 
End stage renal disease (ESRD) is becoming an increasingly preva lent 
illness in Canada. 1 The Canadian Organ Replacement Register A nnual 
Report released by the Canadian Institute for Hea lth In form ati on (CIHI ) 
stated that the number of Canadians I iving with ESRD has tripl ed from 
1990 to 2009.1 Unfortunately. the number of kidneys donated has not 
kept pace w ith thi s increase in demand. In 2009. approximately 38.000 
Canadians are li ving with ES RD. with 59% on dialy is. and 3.000 pa-
tients on th e transplant wait li st. 1 The increase in dialysis treatment also 
comes with a ub tantial cost to the hea lth care system - the estimated 
cost for hemodialysis is $60.000 per pati ent. per year. 1 The C I HI esti-
mates that a renal transplant saves the health care system $250,000 per 
patient over a fi ve-year period. 1 
Due to the shortage of cadaveri c kidneys. there has been an increase 
in using donations from li ving donors. often from an offspring. parent, 
or other geneti cally related family members. Donati ons from unrelated 
donors also make up 30% of the donation poo l. with a porti on being 
strangers to the recipient. Several studies have shown that pati ents re-
ceiving li ving kidney donati ons from either geneti cally re lated and un-
related donors achieve better outcomes th an pati ents rece iving a kidney 
transplant from cadaveric donors.u; Living-donor transplantations have 
been shown to be assoc iated w ith a shorter time to transplantati on, and 
results in a better long-term graft and patient surv iva l6 A s a result of the 
increasing importance of li ving donati on, protocols have been deve l-
oped to accommodate li ving donations: Li ve-Donor Paired Exchange, 
L ive-Donor/Deceased-Donor Exchange. and A ltruisti c Li v ing ondi-
rected Exchange.2 In the Li ve-Donor Paired Exchange. a donor-recipient 
pair (the patient requiring a transplant, and a w illing donor who cannot 
prov ide a matching kidney) is matched with another donor-rec ipient pair 
such that a compatible donor-rec ipient exchange is made. Thi s match-
ing process, or chain, is continued until all rec ip ients receive a kidney. 
In the Li ve-donor/Deceased-donor exchange, a donor-rec ipient pair is 
reassigned such that the live-donor is matched with a rec ipient already 
waiting on the deceased donor li st. In exchange, the fi rst recipient is 
moved nearer to the top of the cadaver li st. Finally. the A ltruisti c L iving 
Nondirected Exchange is true to its name- the kidney donati on comes 
from a generous person who is a stranger to the rec ipient. 
To prov ide suffi cient care for both the donor and recipient. a large 
multidisciplinary team is required to address different facets of care, in-
cluding processe of donati on. matching, and maintenance of care. This 
article will di scuss the li ving kidney donati on process, as well as the role 
and importance of the multidisciplinary team. 
THE MATCHING PROCESS 
The Living Donor Paired Exchange is a program run through the Ca-
nadian Blood Services that identifi es matches between potential li ving 
ki dney donors and transplant recipients in Canada.7 M atching refers to 
th e tests carri ed out by clinical scientists prior to transplanta ti on to mini-
mize the ri sks of acute or delayed graft rejecti on. Thi s in volves ensur-
ing the blood ty pe of the donor and recipient are compatib le. testing 
the histocompati bil ity of the donor kidney. and screening th e plasma 
of the rec ip ient for antibodies against donor ki dney cells.8 To test fo r 
histocompati bili ty the surface molecules pre ent on the donor and re-
cip ient cell s. specifically human leukocyte antigen ( l-I LA) complexes. 
are compared and assessed for similarity." Higher similarity bet\veen 
donor and recipient l-ILA complexes are associated with increased long 
term surviva l rates. and a decreased chance that the immune system of 
th e recipient w ill identi fy the donor cel ls as foreign." Individuals may 
have antibodies against l-I LA complexes circulating in their blood due to 
past transplants. pregnancies. or blood transfusions where their immune 
system was exposed to foreign human cell s. 111 This is why the plasma of 
recipients must be screened for antibodi es targeting donor ce ll s pri or to 
transplantati on in a process known as cross matching.1" 
THE LIV ING KIDNEY DONATION PROCESS 
In this section we wi ll focus on several components of the organ dona-
tion process including assessment of the li ving donor. in formed consent. 
and fo llow-up. These steps typically invo lve the presence of a trans-
plant coordinator. physician. social worker. psychologist or psychi atri st. 
and surgeon. Furthermore. throughout the entire process th ere i usu-
ally a designated li ving-donor advocate who is experi enced in the fie ld 
of transplantation. The advocate can be a soc ial worker. coordinator. 
psycholog ist. psychiatrist. or physician. This advocate should advi se the 
donor independent from rec ipient interests.2 
Assessment of the living donor 
The proces for determining donor acceptabi l ity may vary between 
transplant programs. According to gui delines outlined by the Mu lti-
Organ Transplant Program of the University Hea lth Network ( UI-IN) in 
Toronto, separate hea lth care teams assess potential li vi ng donors and 
rec ipients. Idea lly, thi s would include each donor and recipient w ith his/ 
her own physician. coordinator. soc ial workers. and psychiatry staff. 
Thi s is done to avo id potential conflict of interests. The criteri a for as-
sessment include low medica l/surgica l ri sk, ability to give inform ed 
consent. realistic expectati ons of donati on. vo luntary moti vati on. and 
suffi ciency of economic. practi ca l. and emoti onal re ources to cope w ith 
the donation process. 17 The assessment process includes a ful l physical 
eva luati on to ensure that th e donor is hea lthy and that there are no maj or 
ri sk factors that would lead to renal disease in the future. The donor is 
also evaluated for psychological and soc ial barriers to donati on2 This 
process requi res invo lvement from all members of the multidi sciplinary 
team. Similar processes ex ist aero s Canada wi thin other multi -organ 
transplant centres. 
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In the case of a di spute wi th in the transplantati on team about the suit-
abi l ity of a potential donor. the team may rev iew the criteria used to 
measure suitability. A dditional sources of input may include advice from 
other pro fessional members of th e staff, ho pita! ethics serv ices. legal 
coun el. hospital administrati ve resources. or outside hospital consulta-
tion.1 7 
Informed consent 
Inform ed consent involves confirming the patient's capacity to under-
stand and consent. di sc losing inform ation about the proposed proce-
dure. and ensuring vo luntariness. In the context of organ donation this 
invol ves a detailed discuss ion of the ri sks and benefits to the li v ing do-
nor and rec ipient. T he potential donor should be inform ed about alterna-
ti ve treatment options for the recipient as we ll as the poss ible impact o f 
donati on on the donor 's lifesty le. family relati onships. finances. future 
employment. and abil i ty to rece ive l i fe insurance. Donor and rec ipient 
are typi cally prov ided w ith general information and detail s on program-
spec i fi e outcomes.17 
Wh en a donor appears undecided. counselling can be offered by a 
social worker or psychiatrist to assist the potential donor to solve prob-
lems and address psychosoc ial aspects of this dec ision such as emotional 
issues and how to in fo rm others. Potential donors should be in form ed 
that they can wi thdraw from the process of donation at any tim e w ith the 
full support of the ITansplantation team. A crucial part o f th e assessment 
proces is to ensure that the donor is making his or her dec ision free 
from coercive or manipulat ive intluencesn 
Follo111-up 
It is important to evaluate donor and recipient exper iences including 
medical. psychosocial and economic outcomes. According to U HN 
guidelines, early and late morbidi ty, graft function. mortali ty rates and 
measures o f recipient and donor sati sfaction are documented in an an-
nual rev iew. In the event that a donor requires further care, appropri ate 
care is arranged.17 
T HE IMPORTANCE OF THE INTERDI SC IPLINA RY TEAM 
As outl ined by the prev ious section, the interd isciplinary team plays a 
crucial role in every step of the donation process. In additi on, there has 
been a growing body of ev idence showing the benefit o f interdi sciplin-
ary involvement on quali ty of patient care (both donor and recipient). 
patient sati facti on and surv iva l. In parti cular, a paper by Winsett and 
Hathaway identifi ed three areas of intervention that w ill increase the 
patient 's quality o f life post-transplant: post-tran plant adverse events. 
employment. and social support. 11 Literature has shown intcrdi c iplin-
ary teams have been benefi cial for prov iding support for the patient and 
their family pre- and po !-transplant. A t the Queen Eli zabeth II Hea lth 
ciences Centre in Hal i fax. it was shown that a mu ltidiscip linary k idney 
di sease clinic consi ting of nephrologists, nur e educator and dietitians 
was able to improve metabol ic and blood pressure contro l, and fac ilitate 
the use o f peritonea l d ialys is in late referrals for patients w ith chronic 
kidney disease.12 In a study by Fonouni , Go lriz, M ehrabi . et al. , an in-
terdisciplinary team consisting o f a transp lant surgeon, a nephrologi t, a 
pediatri cian, a radiologist, a psychologist. a tran plant coordinator. and 
a transp lant nur e was shown to have improved staff communicati on. 
patient outcomes and satisfac tion w ith the hospital stay. 13 Several stud-
ies also showed an increase in favourable mental and physical outcomes 
post-transplant w ith the involvement of an in terdiscip l inary team.14·15-1" 
CONCLUSION 
The increasing prevalence o f end stage renal di sease and the shortage 
of cadaveri c kidneys underline the growing importance o f li v ing kidney 
donati on. However, li v ing kidney donation is a complex proce s that 
merits carefu l ethical considerati on . T hi s process invol ves co llaboration 
between multiple health care professions on the side o f the don?r and the 
recipient. Health care workers should have an understanding ot drfferent 
aspects of support that are involved in kidney donation in order to Ill-
form others and alleviate anx iety surround ing kidney donation . Several 
studies have already demonstrated that the current shift towards a more 
integrated and multidi sciplinary approach in kidney transp lantation im-
proves patient care. sa ti sfaction. and surv ival. Therefore it should be 
made clear that the preparation and ultimate outcome of kidney trans-
plantation does not depend solely on the efforts of a nephrologist or 
transplant surgeon. but rather a team effort. 
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MEDICINE AND TECHNOLOGY 
The future of surgical robotics 
Laura Callan , MASc (Meds 2015) and Nancy Chen, BSc (Meds 2016) 
Faculty Reviewer: Dr. Stephen Pautler, MD, FRCSC (Department of Surgery, Division of Urology) 
Robotic surgery is a growing technology with the potential to revolutioni ze surgical procedures. especia lly in the field of urol-ogy. Urology is at the forefront of advances in thi s field. and 
has integrated robotics into many procedures including rad ical cystec-
tom ies. surgical nerve grafting and pyelop lasty. 1 Robotic surgery has 
almost enti rely taken over rad ica l prostatectomy and the role of robotics 
is conti nuous ly expanding. Robotic surgery helps improve patient out-
come b) minimizing the surgeon's movement tremors. increasing range 
of motion. decreasing blood loss. decreasing length of hospital stay. and 
decreasing post-operat i ve pain u Since the field of Urology deals wi th 
very difficu lt and delicate procedures. robotics offe rs an advantage by 
allowing for greater accuracy. flexibi l ity, smoother actions, and greater 
range of motion. 
An important area of advancement for surgical robotic is in the 
field of imaging and vi sual feedback. Robotic surgery can be per-
formed either with a surgeon controlling the robot such as is done with 
the da Vinci system to perform robotic-ass isted radical prostatectomies 
(R'ARPs). or autonomou ly based on a predetermined algorithm such as 
in the case of rad iosurgery for pituitary adenomas.• While autonomous 
robotic systems offer higher prec ision, and ti ssue-damage avoidance. 
surgeon-controlled systems are much better at decision making in un-
structured or chaoti c situations. For the surgeon contro lling the robot. 
vi sual feedback can be attained using endoscop ic cameras; however. for 
autonomous procedures. the con trol program req uires much more detail 
about the patient 's anatomy. 
General ly speaking. there are tw9 types of imaging performed for 
roboti c surgerie : pre-operati ve and intra-operati ve. Pre-operative im-
aging is acqu ired before a procedure and u ed for surgica l planning to 
locate pathologies. a feed-forward system. In computer-guided systems 
thi s can be prob lemat ic since th e images which are used fo r instrument 
nav igation are based on ti ssue location at the time of imaging. However. 
instrument deflection caused by instrument-ti ssue interacti on as wel l as 
ti ssue movement can mean that the instrument position is not as preci se 
as is desirab le. This is especially problematic when dealing with smaller 
anatomica l targets. such as vascular surgery and in paediatrics.' Intra-
operat ive imaging is used to provide close to rea l-time feedback. thereby 
closing the feedback loop and allow ing for adjustm ents throughout the 
procedure. While tor surgeon control led robotic , surgeons have the 
fl ex ibility of compensating via visual feed-back, for autonomous com-
puter-controlled systems this cannot be as easily implemented due to the 
need for code to interpret the vi ual feedback into a control for the robot. 
Research into methods of providing a closed- loop feedback system 
wh ich takes into account instrument deflection and ti ssue movement 
has been carri ed out u ing variou approaches. Meth ods of measuring 
instrument position include computer vision techniques, 6 and electro-
magnetic sensor sy tems. 7 This inform ation then needs to be integrated 
into the computer control ystem to al low for changes in position as the 
surgery progres es. Thi s has been achieved using Direct Image Guided 
Intervention (DIGI) robots. These robots use pre-operative images to 
locate targets and create an initial nav igation protocol. They are also 
connected to an imaging modality which allows for real-time adjust-
ments to thi s protocol. providing greater accuracy and prec ision than a 
feed-forward system. Some challenges to DIGI include compatibility 
bet\\ een robot and imaging modality such as MRI which has a dense 
magnetic field. and most components of the robotic system cannot be 
safe ly used in proximi ty to the magnet. Other problems include spatial 
reso lution, and exposure to radiation if fluoro copy or CT is used8 The 
Robarts Research Institute at Western Universi ty is investigating the use 
of two-dimen siona l transrectal ultrasound (TRUS) to create three-di-
mensional real-time images by sweeping the probe about its axis. This 
technology has been combined with surgeon operated roboti c surgery 
for urologic procedures such as prostate brachytherapy or biopsy.9 
Another area of research wi th the potential to improve computer 
ass isted surger) is haptics. Haptics is the general term used for touch 
feedback. Thi s includes both tactile feedback (i.e. temperature, vibra-
tion. texture. etc) and kinaesthetic feedback (i .e. force and position). 
The majority of the work done regarding haptics in surgical robotics 
is surrounding kinaesthetic feedback. rather than tactile feedback. 10 A 
known dra\\ back of robot ass isted minimally invasive surgery using 
such surgica l robots is the lack of haptic feedback.11 • 13 This drawback 
has been found to be most limiting during complex tasks and can lead to 
difficulty identifying ti ssue ba ed on consi tency ( i.e. between normal 
and tumour ti ssue) and suture breakage during knot ty ing. 14·" 
The reason for the lack or hapti c feedback in such system s is simple: 
the technology required is incredibly complex. The problem of provid-
ing hapti c feedback can be broken down into two distinct tasks: measur-
ing the interact ion to rces and displaying these to rces to the surgeon. 
Measuring of interacti on forces during roboti c surgery has been attempt-
ed in a few different manners. Retrofi tting ex isting surgical manipula-
tors with commercially avail ab le force sensors has been attempted; 19 
however. constraints regarding size. geometry, biocompatibi li ty, steri l-
izab ility and cost have limited thi s approach. 11' Another method is to use 
the distance between desired posit ion and actual position of the manipu-
lator to determine force interactions between the manipulator and the 
environment. Th is method has been implemented with some success; 
however. it is limited by the non-ideal nature of the robot and the en-
vironment. meaning that fri ction and other dynamic forces are di fficult 
to account lor and can be large in comparison to the interaction forces 
between the manipu lator and the pati ent. IO.lo 
Methods of prov iding feedback to the surgeon include direct force 
feedback where motors in the robot contro ls are programmed to recre-
ate the forces sensed by the manipu lator, and the use of other sensOJy 
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feedback such as audio or v isual feedback to represent the forces expe-
rienced by the surg ical instrument. The first method i the mo t com-
monly implemented method: 11' however. enabling a system to prov ide 
force feedback in all directions actuated by the system ( i .e. six degrees 
o f freedom plus gripping ) i not possible\\ ithout implementing a second 
feedback system n U e o f motors to prov ide feedback also introduces 
the poss ibility o f feedback instability which can lead to uncontro lled 
osc illati on . an obv iously undes irable event during surgery'" To get 
around these problem . variou gro ups have attempted to implement 
feedback system s using visual or aud io di spl a) s o f fo rce. 1 ~ -13-1 ' T hese 
system s have experienced som e uccess and have potential fo r further 
implementation as long as they do no t interfere with the surgeon· v iew 
of the ti ssue through the v ideo displ ay o f the endoscopi c camera. 1" 
Robotic surgery allow s prec ise and repeated motions w ith decreased 
fa tigue, moother actions and increased accuracy. fl ex ibilit). and range 
of moti on. especially in small confined anatomical locations such as the 
male pelv is during pro tate surgery. However, there are still limitations 
in v isual and hapti c feedback. These limitations. as we ll as training o f 
surgeons. have stunted th e growth o f this fi eld in ome ways: however. 
as described. intensive re earch is underway. It is c lear that in certain 
situations. it is be t to rely on image guidance, allow ing the surgeon to 
be guided by more than w hat is v isible through the visual fi eld . For 
thi s to happen. imaging modaliti es which allow for greater compatibili ty 
w ith the surg ical robot w hile m aintaining as low radiation dose to the 
patient and surgeon as possible will need to be deve loped beyond the 
current techno logy. Similarl y. to ben er enable thi s physic ian to identify 
spec ific ti ssues. haptic techno logy and its implementati on into surgery 
w ill also need to be furthered . As these techno logies become increa -
ing ly incorporated in the fi eld of surg ical robotics. we can expect rapid 
growth in th e number of surgeries to m ake the transition from traditional 
to robotically -assisted or even fully automated. 
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Interview with Dr. Faisal Rehman 
Joyce Zhang (Meds 2015) and Sissi Cao (Meds 2016) 
Faculty Reviewer: Dr. Faisal Rehman MD, FRCPC, M.Ed (Department of Medicine, Division of Nephrology) 
S !epping into Dr. Faisal Rehman·s office. \\e could not help but notice the count ies degrees. teaching awards. photographs and thank-you notes th at decorated his wa ll s. On a Friday afternoon. 
we were luc!..··y to sit down and speak with the distingui shed clinician. 
teacher and boxer at the Schu lich School of Medicine & Dentistry. 
A s the Nephrology Site Chief and the Director of Internal Medicine 
clerkship program at ni versity Hospital and chair of the genitouri-
nary block in the first-year curri cu lum. Dr. Rehman has a longstanding 
history \~ith Western Uni versity. After completing a Bachelors degree 
in pharmacology at the Univer ity of A lberta and a Medical degree at 
Queen·s Uni versity. Dr. Rehman began his training in internal medi-
cine at Schuli ch . He comp leted his nephrology fellowship in 200 1 and 
went on to pursue a Masters of med ica l educati on at th e University of 
Toronto. Dr. Rehman returned to Western Uni versity where he has since 
establi shed a rewarding and successful academic medical career. 
Dr. Rehman developed a fascination with medicine at a young age 
under the influence of famil y and friends in the profession. He set his 
mind on internal medicine after exploring clinical observerships but 
admitted that choosing a specialty was a more difficu lt challenge th an 
being accepted to medical schoo l. Dr. Rehman recognized near gradu-
ation that intellectually stimu lation through problem solving was what 
he enjoyed most in med icine, leadi ng him to choo e a residency in in-
ternal medicine. Internal med icine·s range combined with Dr. Rehman·s 
interest in longitud inal care ultimate ly drew him to the fi eld of nephrol-
ogy. He loves nephro logy. he tells us. because it involves complicated 
physiology, offers diversity - from transplants to glomerular nephritis to 
diabetes- and allows him to help patients in va rious stage life: from 
disease in the outpat ient clinic to dialysis, to transplant, to transplant 
failure and return to dialysis. 
When asked about the future direction of research in his fi eld. Dr. 
Rehman says he sees portab le art ifi cia l kidneys helping restore indepen-
dence and improve quality of life fo r the chronic hemodialysis pat ients 
he works closely with . l-Ie is hopefu l new kidney technology cou ld be 
translated into clini cal practice since dialysis is an inconvenience and 
unpleasant experience for patients. In addition. Dr. Rehman believes that 
the delivery of care needs to be altered to accommodate the increasing 
prevalence of chronic kidney disea e . .. Unless we can have novel in ven-
ti ons like the artifi cial kidney, I see our dia lysi population exp loding. I 
see our CKD (chronic kidney disease) cl inics being overwhelmed. Un-
fortunately disease prevention has not gotten a lot of hype." 
A s for what he enjoys most about his career. Dr. Rehman 's response 
was trongly echoed by the awards on his wa ll s: ·' t love to teach:· he 
says. and especially being around students to teach them in the early 
stages of their careers. In add ition to trad iti onal teaching in the class-
room. he has served as honorary president of the Hippocrati c student 
counci l and other class council s. Even his research interests complement 
med ica l educati on. The projects he has overseen have included artificial 
kidney modeling. training renal fellows and developing nephrology-
related research filters. In his words ... the best reward is to see a student 
mature and develop to the point they know more than you. And t ·ve seen 
that in my students who are now consultants who have really excelled 
in research or medical education. It makes you proud that you have con-
tributed to that person developing.·· 
We could not leave Dr. Rehman's office without satisfying our cu ri-
o ity about his chari ty boxing career that lent him the name King Faisal. 
Outside of medicine. the physician indulges in boxing, which he enjoyed 
watching as a child and training in as a youth. When the department 
needed to raise money for kidney research 5 years ago, Dr. Rehman vol-
unteered to rai se money for the Kidney Clini ca l Research Unit, thinking 
at the time . .. I f t·m going to do thi s. I will do my kind of event.'' With 
th e help of a friend who was an international boxing champion. the first 
Knock Out Kidney Disease annual gala was put together in a little over 
a year in 2008. Not only did Dr. Rehman mastermind the organization 
of the event. he also trained to fight in the ring in order to rai se more 
money. His initiati ve and training paid off in a huge way : the event has 
rai sed over $600 000 over the past 4 years for the Kidney Clinical Re-
search nit and the Mathew Mailing Centre for Transitional Transplant 
Studi es at Un iversity Hospital. 
Dr. Rehman also shared with us one of his most memorab le patients, 
which was an incredible case of human resilience. This patient was Ms. 
AL. a single mother of five young children.\\ ho suffe red from systemic 
lupus er) th ematous ( LE) and presented wi th severe skin rash. hema-
touria. and proteinuria. Even though her kidney disease of membranous 
lupus nephritis was initial!) managed accordingly with immunosuppres-
sant • she started to develop severe hemoptysis secondary to lupus vas-
cu liti s of the lungs. She experienced further worsening of kidney func-
ti on (acute kidney injury) and required multip le transfu sions of 20 to 
30 units of blood. Any further management of immunosuppression and 
plasmophoresisju t seemed to make matters worse. She had a pro longed 
hospital stay of 2 months, deve loped myocarditi s and lost a sionificant 
amount of weight that severely lim ited her mobility. But just \~hen the 
story could not get any worse. the pati ent sudden ly got better. She start-
ed to recover after Dr. Rehman stopped one o f her immunosuppressive 
med rcatr ons. Now. she leads an active and fu ll li fe, does charity work 
for a lupus society and is healthy enough to trave l all over the world. Dr. 
Rehman can only speculate that perhaps the powerfu l immunosuppres-
sron meant to contro l her lupus had essentially functionally ablated her 
bone marrow as a side effect. It was a memorable case for him because 
she had been so close to death but then spontaneously got better with no 
more signs of lupu . l-Ie says, ·'this case helped to reinforce that 1 need 
to constantly re-evaluate what I 'm doing, and to not stick to a recipe. It 
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made me realize that medicine is an art for some patients."' 
For any medical students considering the fie ld of internal medicine 
and perhaps nephrology. Dr. Rehman has some words of w isdom to of-
fer. .. In my opin ion nephrologists are the classic interni sts. They have to 
kno\~ everyth ing about the body."' he says. A nephro logist is someone 
who enjoys compl icated physio logy and longitudi na l care of pati ents. 
ephrologist work in a unique fie ld where pati ents can never be signed 
off. They may need to be fo llowed from age I 0 to 12 years old until 
death and everything in between: from dialysis. a transplant. back to 
dialys i . and th rough fami ly catastrophe. Lastly. he tell s us that. " the 
fi rst few year of medical school are not conducive to learning about 
what you want to do when you grow up. What I found help ful is to really 
max imize the opportunity to do observerships to get a fl avour of what's 
involved to make a better decision. Tryi ng to narrow it down between 
surgery and med icine up front may be help ful." 
A lthough many clin icians lead rewarding academic medical careers. 
few can claim their students know them as King Faisal. Dr. Rehman 
exemplifi es how extensive a phys ician's invo lvement in medicine can 
be. His in vo lvement in patient care. medica l educati on. student initia-
ti ves. research and fundraising all refl ect his di verse passions and speak 
to his abili ty to maintain balance in his life and career. It is cl ear that Dr. 
Rehman loves what he does and his patients and tudents clearly appre-
ciate all the time he gives. 
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Fever with incontinence in the elderly: an approach 
for emergency medicine 
Anthony Chow (Meds 2016) and Elaine Tang (Meds 2015) 
Faculty Reviewer: Dr. Derrick Pringle, MD, FRCPC (Division of Emergency Medicine) 
k 72-year-old man develops a high fever and is taken to the ER by his concerned w i fe and daughter. During the intake interview. he wi fe report that th e man is experi encing worsening inconti-
nence and occasionally complains of dysuria. Past medical records indi -
cate that the man is alread) being treated and fo llowed for hypertension 
and early A lzheimer · disease. but the wife notes that it has become 
increasingly di fficult to manage her husband 's confusion over the past 
week. 
A n emergency physician receives the above inform ati on from the 
tri age nurse. The nurse adds that the man and his family have been 1\ ail-
ing for two hours and all three appear qu ite distressed. How could such 
a situation be managed? 
GERIATRICS AND DEMENTIA: CONSIDERATIONS FOR THE 
BEDSIDE 
The age of a patient carries important implica tions for pati ent assess-
ment and treatment. The physiology of a hea lthy. older adult adapts to 
functioning with tissues that have deteriorated with age. achieving a 
state of compromised balance termed homeostenosis. ' Patients in thi 
subpopulati on thus have a reduced capacity to respond and adapt to the 
stresses brought on by acute illness and are more vulnerable to such 
insults. 
Thi s affects patient assessment. as it may be diffi cult to distinguish 
symptoms of underl y ing disease from th ose of acute i llness. Determin-
ing the pati ent"s medical hi tory. current medicati on regime and soc ial 
circumstances is also challenging in an emergency sctting2 Prospecti ve 
treatments are l imited in that they must not exacerbate or interact with 
existing conditions and treatments. Polypharmacy, in parti cular, di pro-
portionately affects the elderly and contributes to increased adverse drug 
events. physician visits, emergency admissions and hospital isati ons3 
All the above can be further compli cated by dementia in the pati ent. 
The patient 's history may need to be obtained from fami ly members or 
caregivers present in the ER or staff at a care faci l ity, potentially lead-
ing to mistakes in interpreting symptom severity or mi sing incipient 
problems entirely. Furtherm ore, the patient may be unwilling or unable 
to participate in diagnosti c or intervent ional measures that become indi-
cated through the course of care.' 
Pain management is especially diffi cult and no less important for pa-
ti ents with dementia. Though not ideal. primary care physicians must 
take care to detect surrogate markers of pain, uch as confusion. gestur-
ing or posturing. through the physical examinati on.' 
Returning to th e case, it is determined upon examinati on that the pa-
tient does not have the capac ity to make his own medical dec isions when 
he is unable to g ive his own name. Fortunately, his wife and daughter 
are attenti ve and meticulous principal caregivers. On request, they pro-
duce a l ist of medications th e patient is taking currently (ch lorthalidone 
and rami pril for hypertension. galantamine for dementia, cyclazine for 
nau ea. loratadine for seasonal al lergies) and confirm that thi s degree of 
confusion is highly atypical. Unexpected change in cognitive status is a 
hallmark of pain in dementia so I 000 mg acetaminophen is ordered.; 
aft er establ ishi ng that the patient would have no known allergy or drug 
interacti ons. Vital signs are assessed and no abnormal it ies beyond high 
blood pressure ( 145/90) and high oral temperature (40.5 °C) are found. 
SIGNS OF INFECTION IN THE ELDERLY 
Fever as a sign of in fection can operate quite differently in older adults. 
Ageing-mediated impairment of th ermoregulati on means that fever can 
fai I to occur in up to hal f of elderly persons. despite the ex istence of I ife-
threatening infecti on. Even norm al body temperature can be lower than 
expected in the elderly and even lower in those with dementia due to the 
same age-related changes.'· 
G iven th e above. the fi nding of fever in th e pati ent is a definite cause 
for concern . A n explanati on for this sign is sought in th e next prominent 
set of symptom : worsening incontinence and dysuria. 
URI NA RY I NCO TINENCE: DIFFERENTIAL DIAGNOSIS 
Age is the greatest determinant of urinary incontinence ri sk. Many fac-
tors that negati vely affect normal micturi tion are more likely to occur 
v. ith increasing age. With respect to transient incontinence. these in-
clude urinary tract infections (UTls). genitourinary muscle pathology, 
acute i llncsses that mandate immobi I isation or catheteri sation, fecal 
impacti on, medicati ons with autonomic etTects or psychological expres-
sion o f dependency or rebellion7 
Though female are much more likely to experience incontinence 
than males. several urologica l causes of incontinence are exclusive to 
male . For younger males. in particular, urethral and prostatic infection 
secondary to a sexuall y-transmitled disease is a frequent cause of in-
continence.' In older men, incontinence is more often related to prostate 
disease. Prostate surgery is th e most common cause of stress urinary in-
continence in men and prostate hypertrophy may cause overflow incon-
tinence by compressing the bladder.'' M ore importantly, UT!s are much 
more common in older th an younger men, with an incidence approach-
ing that seen in women.' 
In the emergency department, life-threatening causes such a cau-
da equina syndrome, spinal cord compress ion and paraspinal abscess 
must additionally be rul ed out i f suspected. A bacterial abscess cou ld 
be consistent wi th typical infection-related observation , like fever. and 
can lead to both the other conditions by direct or vascular compression. 
A n MRI i necessary for rulin g out thi s po s ibility. ~<' I f additional lower 
body motor or sensory symptoms are present, it is important to more 
defini ti vely determin e whether the cauda equina or spinal cord is af-
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In the present ca e. the physica l examinati on is continued wi th an 
awareness of poss ible urologica l disease. Palpati on of the abdomen does 
not reveal a distended or swollen bladder. which would have suggested 
overflow incontinence.7 
A s fever. dysuria and incontinence together point convincingly to-
ward a urologic prob lem. an abdominal CT scan is not indicated at this 
point. Instead. blood is drawn for routine chemistry. A urethral catheteri-
sati on is performed to obtain a steril e urine sample for urinalys is and 
urine culture. The patient is mildly uncooperative but accepting of oral 
med icati on. so oral sedatives are adm inistered. '2 A bedside ultrasound 
bladder scan is ordered to rul e out urinary retention and th e need to leave 
the catheter in siluu 
A n hour later. several r~ports are fonvarded from the laboratory. 
Blood urea nitrogen (BUN) and creatinine are both normaL indicating 
good kidney function. especia ll y for the patient's age.'• The routine uri-
nalysis report, on the oth er hand. shows bacteria and l ~ ukocytes in high 
numbers in the urine (bacteriuria and pyuria) and the nitrate test is posi-
tive. Thi s and urine turbidity shift suspicion to urinary tract infection 
(UTI) as opposed to the more common urethriti s.' A nned with all of the 
above, the doctor return s to the bedside. 
URINARY TRACT INFECTIONS: DIAGNOSIS 
In the elderly. investigat ion for T i s needs to be justifi ed by a high de-
gree of suspicion because urinary incontinence and dysuria alone are 
very common and non-speci fi c. as discus ed. In fact. conditions like pol -
laki uria (frequent urinati on) and nocturi a (night urination) are estimated 
to be present in over 50% of individuals over 60 years of age.15 In this 
population, even individuals w ithou t infect ion often present 1vith the 
classic triad of UTI diagnosis: frequency. urgency and dysuria. 16 
Diagnosis of UTI in an older adu lt. then. otien depends on non-
urological indications. These commonly include a general decrease in 
day-to-day function. loss of v1eight or appetite. decreased alertness or 
flank or abdominal tenderness. For patients w ith dementia. behavioural 
deterioration and confusion can be extremely important symptoms. I(' 
For the current patient. fever. confusion. dysuria and incontinence 
create a strong suspicion of UTI, strengthened by the subsequent find-
ings of bacteriuria and pyuria. Upon further questioning. the daughter 
additionall y confinns that lately the pati ent's appetite has decreased no-
ticeably. 
URINARY TRACT INFECTIO S: MANAGEMENT IN THEEL-
DERLY 
Diagnosis and treatment ofUTis in th e emergency department frequently 
occurs without formal bacteria culturing.' 7 Though it is possible for as-
ymptomatic urologic bacteremia to reso lve spontaneously in the elderly, 
seri ous complications like renal damage. pyelonephriti s and sepsis may 
occur, so it is prudent to treat all UTi s in the elderly as complicated."' 17 
For most cases. a I 0- or 14-day course of the broad-spectrum antibi-
otic levofloxacin is indicated. Particularly for elderly men. a fluoroqui-
nolone like levofloxacin has the additional benefi t of high prostate gland 
penetration. Recurrence and relapse are commonly seen in the elderly, 
so proper follow-up must be arranged. 16 
Returning to the case, the pati ent is prescribed oral levofloxac in. 250 
mg per day for 14 days and allowed to take acetaminophen as needed. 
Given the fever and neuro logical symptoms. however, the pati ent is con-
sidered at ri sk of developing sepsis. so it is decided w ith the wife and 
daughter 's consent that it wou ld be most prudent to admit the patient to 
the medicine service. 
THINKING ON YOUR FEET 
The next clay. the patient's serum lactate remain s unremarkable and 
repeat measurement of his vitals - particu larly heart rate and 0 2 satura-
ti on - return norm al findings. He is cooperative and much more aware 
or hi s situation. correctly provid ing his name. the approximate date and 
the fact that he was in a hospital. " Sati sfied wi th the above improve-
m~nts . the phys ician discharges the patient and asks the wife and daugh-
ter to help fill and administer the r~mainder of the prescripti on. The) are 
also instructed to bring the patient to ee his fami ly doctor in one week 
to ensure clearance of the microorgani sm. confirm relief of neurolog i-
ca l symptoms and consider management of incontinence. i f it becomes 
chronic. Referral to a urologist is deemed unnecessary unless further 
complicat ion occur. 
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Diagnosing in the dark: atypical proteinuria 
etiology 
Stephen Cornish (Meds 2015) and Eric Roszell (Meds 2016) 
Faculty Reviewer: Dr. Faisal Rehman, MD, FRCPC, M.Ed (Department of Medicine, Division of Nephrology) 
zebra is a member of the species of Afri can equids. of the horse 
family, whose appearance i defined by striking black and 1vhite 
tripes. These animals are rarely seen outside of their nati ve 
continent. except for their requisite presence in zoos. menageri es. and 
circuses. When we think of someth ing that is common. a zebra may 
defi ne the direct antithes is to our notion of commonality. L ikewise, a 
zebra patient is, for a physician. a peculiar blend of an exciting presenta-
ti on and a frustrating diagnosis. The helpful adage "common things are 
common" can be summarily thrown out of the nearest window when 
dealing with the contents of the Zebra Files. 
Our case begins wi th an 80 year old gentleman presenting to his 
primary care physician with an acute history of leg swelling and uri-
nary frequency over the past three weeks. An eva luati on of the present 
complaint determined that he wa al o experi encing a reduced appetite. 
nausea and vomiting. On examinati on. the man ·s blood pressure was 
138/78. and the lower ex tremi ties demonstrated the fea tures of pitting 
edema. lnve Ligations were ordered. and returned as follows: blood 
urea nitrogen (BUN) of 7.3 mmoi/L (normal range 2.9 - 8.6 mmoi/L). 
serum creatinine (Cr) of 45 7.6 umoi/L (norm al range 53 - 115 umoi/L). 
and a serum album in leve l of 25 giL (normal range 35 - 50 g/L ). Uri-
nalysis was performed. which detected the presence of protein (graded 
as a 3+) as well as gluco e in the urine. ~~ ith no remarkab le microscopic 
finding .1 With these results and the clinica l picture revea led. we can 
begin to hypothesize. 
The finding of pitting edema on phy ical exam suggests an accumu-
lation of fluid in the interstit ial space of body ti ssues. Fluid typica ll y 
poo ls in dependent areas of the body like the legs and feet. 2 This is 
reflected in our patient, who had noticed an abnorm al swelling of his 
lower limbs. Pitting edema i a ign of vo lume overl oad in patients. 
which results in excess fluid eeping out of the vasculature into the inter-
stitial space of body tis ues. There are everal mechanisms by which this 
vo lume overl oad phenomenon can occur. For the ake of brev ity. heart 
fai lure. li ver diseases such as cirrhosis. renal sodium retention. nephro tic 
syndrome, drug-induced. and idiopathic edema are all potential culprits. 
espec ially in an indi vidual of advanced age.3 Differentiating between 
th ese etiologies is critical in order to proceed. 
Building on our understanding of this pati ent 's volume status. we can 
examine the results of the initial investigati ons. Both urea and creatinine 
were found to be elevated, which indicate impairment of renal fun cti on. 
The key to the picture here is the urinalysis test. The significant pres-
ence of protein in the urine, classified in this case as proteinuria of 3 out 
of a poss ible 4 degree of severity, should not be seen in a healthy person 
and is an indicator of disease. 
A differential diagnosis for heavy proteinuria would include glo-
merular causes such as glomerulonephriti s, , diabetic glomeruloscle-
rosis. systemic lupu erythematosus. amyloidosis. and va culi tis. Other 
causes may include. monoclonal proteinuria. multiple myeloma. I) m-
phoma. or other neoplasia. 4 Renal functi on is dependent upon fi ltra-
tion in th e glomerular un it. resulting in the remova l of 11astes and the 
retention of blood ce lls and proteins. Fai lure to retain proteins sugge Is 
damage to the glomerulu. the fi ltrati on unit of the kidne) . The absence 
of blood in the urine. or hematuri a. is also help fu l. Heavy proteinuria 
without hematuri a fa ll into one category of renal disease (nephrotic). 
while the combinati on is indicati ve of a di fte rent type of pathology (ne-
phritic)5 The measurement of a low albumin in the investigation of thi 
patient is refl ecti ve of the heavy proteinuria. 
The patient was referred by his primary care phys ician to a nephrol-
ogy clinic for further evaluati on. Repeat urinalysis was perform ed. A 
24 hour urine co llection for protein was perfonned. which is more help-
ful for evaluating the amount of proteinuria than a dipstick urinalys i 
The patient was losing 20.7 g of protein over a 24 hour period in hi 
urine. This more focused analysis returned another curious resul t: in ad-
dition to the prev iously detected proteinuria. trace blood also appeared 
in the urine. Microscopic analys is identifi ed I 0-20 red blood cell s per 
magnifi ca ti on fie ld, with some granu lar casts. 1 The pati ent has now 
demonstrated some degree of hematuria observed in the sett ing of heav) 
proteinuria. 
The finding of hematuri a shifts the diagnostic focus away from a 
nephrotic syndrome, which is categori cally limited to protein wasting in 
the urine. and usually not blood. Glomerulonephriti s is an inflammatory 
process defi ned by the presence of red blood ce ll casts or d) smorphi c 
red blood ce lls in urine. moderate prote inuria hypertension. and renal 
fa ilure.'' Causes of the nephriti c syndrome all relate to vari ous defecti ve 
autoimmune proce ses: damage from these circulating factors occurs 
progress ive ly as these factors accumulate during glomeru lar fi ltration. 
The underly ing cause of the glomeru lonephriti s can be determined by 
serologica l tests for these autoimmune factors. 
aturall y. in our "Zebra" patient. the usua l suspects in the nephriti c 
syndrome (anti-nuclear anti bod ies. A CA and anti-GBM antibodies. 
cryoglobulins. Hep C antibody. ASO titres) turned up negati ve. How-
ever. two proteins (C3 and C4) were found to be abnormally low.1 These 
are norm ally invo lved in the complement cascade vital to the body's 
immune respon e. 
A renal biopsy was performed to determine the glomerul ar pathol-
ogy. Light microscopic eva luation showed classic characteri stics of a 
membranoproli ferati ve glorneru lonephriti . with form ati on of patholog-
ica l crescents in 50% of glomeruli . A Congo red stain was performed on 
the biopsy ample: it returned w ith a negati ve result. ruling out renal am-
y loido is. 1 A fter a circuitous diagnostic route. the electron microscop) 
and immunofluorescence on the kidney biopsy specimen did prov ide an 
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ans" er. The architec ture of the glomeru lar basement membrane was be-
ing di srupted by randomly arranged fibri llary deposits. Final d iagnosis 
was determined: fibril lary g lomerulonephriti s with crescent form ati on. 
in th e presence of hypocomplementemia. 
Fibrill ary g lomerulonephritis is an uncommon di ease of th e g lom-
eru lus leading to renal dysfu nction .7 T his dys functi on is caused by a 
buildup of randomly arranged fibrillar deposit in the glomerular base 
membrane and mesangium.8 The di ease was first distingu ished in 1977 
from amy lo idosis on the basis that congo red stains. which stain amy lo id 
fibers. were negati ve in several patient" kidne) biopsies.' Fibri ll ary 
g lomerul onephriti s has been associated with different malignancies, 
monoclonal gammopathies. and autoimmune di sorders.7 Despite the 
thorough characteri zati on of fibri ll ary g lomerul onephriti s, the pathol-
ogy of the disorder is not fully understood although it is kno11 n that the 
fibrillary depo its are derived from immunoglobulin .'' 
Crescents formation. as seen in our ··zebra·· patient. is seen in ap-
prox imate ly 20% of cases of fibrillary g lomeru lonephriti s. Crescent 
result from a nonspecific respon se to severe injury of the glomerular 
capillary wall. These crescents can invo lve anywhere from 10% to 80% 
of the g lomeru lus. ' Since ere cents result from a nonspec ifi c re ponse. 
they can be seen in any type of severe glomerular di sease. 
A lthough fibri ll ary glomerulonephriti s is not generally considered a 
rare disease. as it is present in approx imately I% of kidney biopsies. the 
added complication of hypocomplementemia has only been reported on 
one other occasion in the literature.7 H) pocomplentemia can refer to low 
levels of the molecular mediators of complement: in our ··zebra·· pati ent 
it refers to th e decreased amount of 3 and C4. 
The treatment of fibri ll ary glomerulonephriti s w ith crescent form a-
tion and hypocomplementemia has not been we ll e tablished due to the 
rarity of the condit ion . nfortunately. many of the treatment option for 
other types of g lomerul onephriti s. such as teroids or cytotox ic agents. 
are ineffecti ve on fibrillary glomerul onephritis7 Con erva tive use of 
angiotensin inhibiti on is often used to contro l blood pressure and slow 
th e progress of the disease.' " Some o f the th erapies that have been at-
tempted to ome uccess in vo lve the use o f g lucocorti co ids. prednisone, 
cyto toxic agents such as cyc lophosphamide. and rituximab. 11 
The prognosis for patients with fibri llary glomerulonephriti s is o ften 
grave due to th e dearth of treatment opti on . The expected tim e cour e 
can be estimated at the tim e of a renal biopsy by different hi tologica l 
features seen under li ght microscopy.12 Approximately 50% o f pati ent 
w ill progress to end-stage renal di sease w ithin t'A o to six years. A mong 
the remaining patient . only 10% achieve complete or partial remission 
while 40% have progressi ve renal di ease. '" With thi outlook, our pa-
ti ent may have become one of the grow ing numbers of patients who are 
dependent on renal d ialys is therapy. a d i fficult rea lity that defines the 
medical care of so many elder! ) patient . 
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The barriers surrounding hemodialysis for patients 
with ESRD: improving access since 1945 
Justine Denomme (Meds 2015) and Wendy Cui (Meds 2016) 
Faculty Reviewer: Dr. Shelley McKellar, PhD (Jason A. Hannah Chair in the History of Medicine) 
Hemodialys is is one option for renal rep lacement therapy in peo-ple wi th End Stage Renal Disease (ES RD). It is required when a person· kidneys are unable to comp lete th eir normal func-
tion. that of maintaining the normal intracell ular and extracell ular fluid 
env ironment with in the body. 1 It en tail s remov ing excess fluid. as we ll 
as waste such as urea. while replacing necessary substances such as 
bicarbonate.1 In thi s article. we present some of th e barriers surrounding 
the implementation of dialysi for patients and explore how some of 
th ese barriers were overcome. 
EARLY DEVELOPME NT A D IMPLEMENTAT ION OF HEMO-
DIALYS IS 
The first successful use of hemodialysis occurred in the Netherlands in 
1945 by Dr Willem J. Kolffwith a machine dubbed the ·'artifi cial kid-
ney.'"2 A 67-year-old woman suffer ing from acute kidney injury was 
nearly anuric. but wi th 11 .5 hour of dialysis. her blood urea nitrogen 
and serum potassium levels dropped and she eventually made a full re-
covery. Dialysis. still experimental then. wa re erved. as in thi s case. 
for failures of conventional treatment.2 Interestingly. a Canadian sur-
geon, Dr. Gordon Murray, also invented a hemodialysis machine around 
the same time as Dr. Kolff3 In 1946, he successfull y dialyzed a woman 
in a uremic coma at Toronto General Hospital. Despite these succes es. 
hemodialysis wa initially met with concern from physicians regarding 
afety and efficacy. especially since treatment course was detennined 
largely by tri al-and-error and few peop le were trained to operate the 
machineH However, throughout the 1950 's. hemodialysis gained popu-
lari ty and improvements and modificati ons were made to faci litate treat-
ment and improve outcomes5 It was indicated primarily for patients 
with acute kidney injury who on ly needed to be dialyzed temporari ly 
rather than for ESRD as it wa difficult to maintain vascular access 
for repeated dialysis to take place. 5 This problem was reso lved in 1960 
when Dr. Beld ing H. Scribner and co lleagues introduced an arteriove-
nous shunt. which kept the rad ial artery and forearm vein in the arm of 
the patient connected using Teflon tubing.6 Thi hunt remained on the 
patient to maintain vascu lar access, faci litating connection with the he-
modialyzer whenever dialy is was needed.6 
O NCE HEMODIALYSIS BECAME AVAILABLE TO THOSE 
WITH ESRD, WHO RECEIVED CA RE? 
The Scribner shunt made hemodialysis a viable option for ESRD. In 
1962. Dr. Scribner opened the world 's first outpatient dialys is centre 
in Seattle. 7 The Seattle Artific ial Kidney Centre consisted of on ly three 
sets of dialys is eq uipment w ith limited staff. Thu , the centre formed 
two committees to detennine wh ich patients were be t suited for hemo-
dialysis. The first cons isted of nephrologists who ensured patients met 
stringent medical criteria. The second, the Admi ssions and Policy Com-
mittee. consisted of two phys icians, a Christian minister. lawyer, house-
w ife. businessman. and labour leader. It was also nicknamed ··the God 
committee'" as its rol e was to asses the ·· relati ve worth .. of a candidate 
to th eir fami ly and to soc iety at large and chose which pati ents would 
survive and which would die from their di seaseY Choices were al-
101\ ed to be guided by each member ·s conscience and pati ents cou ld be 
eva luated on marital tatus. occupation. income. education. emoti onal 
stability. future potential. gender. and ageY Successful candidates were 
usually those who were hard-working. had many chi ldren. were acti vely 
invo lved in church and communi ty affairs. but had few monetary sav-
ings such that i f th ey died. the state would have to support th e family. 
As a result. th e decisions of the Committee were large ly biased tO\\ ard 
White. Protestant. middle-class men. ~ Committee members agonized 
over these difficult decisions and criti cs fe lt that determining ··social 
worth .. was unethical and sugge ted that dec ision-making be based on 
a method that does not penn it the compari son of socia l worth among 
indi vidual s. such as choosing by lottery.7· 111 Fortunately. such committees 
became unnecessary a hemodialysis became more widely avai labl e. In 
1972. U.S. Congress agreed to prov ide dialysis in end-stage renal dis-
ease for those who could not afford it.9 
The initial situati on in Canada is not unlike that in the United States. 
Prior to the implementation of the 1966 Medical Care Act. regular di-
alysis treatm ents were only offered in a fe\\ hospital due to prohibiti ve 
costs.11 Again. the question of who wou ld receive treatment and how 
such al locat ions would be detennined posed a dilemma for physicians 
and policy-makers. Selection committees regulated who rece ived dialy-
sis. based on criteria uch a age. the stage of renal disease. absence of 
other comorbidities. and suitabili ty for kidney tran plantation . It was the 
death of a young man from kidney disease in Montreal that precipitated 
the creati on of the charitable Kidney Foundation of anada in 1964. 
dedicated to advocacy. research. and support for Canadians w ith renal 
disease. Eventua lly. under Medicare. the cost of dia lys is was fully cov-
ered. allowi ng patients with renal disease access to previously unattain-
able I i le-sav ing care. 11 Advocacy for hemodialys is has saved many I ives. 
In 2009. 22,3 I 0 Canadians \\ ith E RD were being treated w ith dialy -
sis.1 2 A lthough it is known that renal transp lantation is the best treatment 
for ES RD. the number of kidneys ava ilable for transplant i not increas-
ing as sharp ly as diagnoses of ESRD and demand for hemodialysis is 
expected to increase in the future. 12 
DEVE LOPMENT OF HOM E DI A LYSIS 
Even with improved access, hemodia lysi , although li fe- av ing. is very 
time-consuming, invasive. and may negatively impact quality of li fe. 13 
One aspect of initial treatment wa that most patients needed to trave l to 
a hospita l and dedicate everal hours a week to being dialyzed. A method 
that circum vents thi s necessity. promoted in Canada by Dr. Robert U l-
dall and Dr. A ndreas Pierratos at the Uni versity of Toronto in 1993. is 
home hemodialysis. Thi s method allow pati ents to perform dia lysis at 
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home during sleep fo r most. i f not all. nights o f the 11 eek." A lthough 
patients must be trained. home dialys is has been associated w ith im-
proved quality of life and a higher cost uti l ity compared to traditional 
in -center hemodialys is.' 5 Whil e home dialys is peaked in 1993 at 37.4% 
of all d ial) sis in Canada. in 20 I I th at fi gure w as only 23 -2-1% in On-
tari o.11 Home dialy i can be di f fi cult to implement and unsuitab le for 
some pati ents, but it o ffers an alternati ve fo r pati ents who would prefer 
to be trea ted at home. 
EXPANSION OF DIALYSIS TO RURAL SITES 
Canada is a vast country and many communities are isolated from large 
hospital centres containing dial) sis units. Many pati ents are faced w ith 
a shortage of dialys i stations in their area and have a limited abilit) to 
select their preferred location or chedule for dialysis. Patients li v ing in 
rural areas may need to make hours-l ong dri ves to the nearest hospital. 
a heavy burden in vu lnerable populati on uch as the elderl y and d is-
abled.'6 A del ivery model proven to be safe and effecti ve in Ontari o is 
the satell i te mode l. in which rural satellite sites are paired w ith a larger 
centre or ··hub .. to ensure that whil e patients may recei ve hemodialys is 
in a rural sett ing. the) are still granted access to an experienced nephro l-
ogy team.17 A n example of a sa tellite dialys is unit can be fo und in God-
erich. Ontari o. a town of 8,000 residents about an hour north of London, 
Ontario. Opening in 200 I as a atellite of the London Hea lth Science 
Centre Renal Program. the fac ility can accommodate 12 patient per 
day who would otherw ise need to travel to London for hemodialys is." 
A nephrologi t from London vi its approx imately once a month for pa-
tient assessment and adj ustm ent of medications and conference calls are 
made to discu s patient care on a 1\ eekly basis. A lthough such fac ilit ie 
are primaril y for the most stabl e pati ents requiring d ialys is. they have 
empowered smaller communiti es and helped alleviate some of the added 
di fficulties of having ESRD in a rural setting." 
CONCL SIONS 
Access to hemod ialys is has improved ove r th e years and patients are 
now empowered w ith more options for treatment. inc luding home di-
alys is and access to atellite si tes. However. accessibility to trea tment 
remains an issue fo r chronic ki dney di ease and ESRD pati ents. A s the 
prevalence o f k idney disease ha increased. so has demand for dialys is. 
from more than 5 900 Canadians on dialys is in 1990 to 22 300 in 2009. 
an increa e from 53% to 59% of all ES RD pati ents. 11 Furthermore, for 
many patients, transplantati on remains the ultimate goa l o f treatment. It 
is known that renal transplantat ion is &enerall y more effecti ve at treating 
pati ents w ith ESRD and those transplanted report a greater qualit) o f 
li fe.' " In addit ion. thee timated cost for hemodialys is is approx imately 
$60 000 per year of treatm ent, per pati ent, whil e the cost for a one-time 
kidney transplant. inc luding annual maintenance medicati on. is $29 000. 
T he sav ings are $250 000 over a fi ve year period, especially relevant in 
I ight of many recent cuts to hea lthcare in Ontario. '1 
Due to limited acce s to donor organ . guidelines have been deve l-
oped to determine which patients are eli gibl e for kidney transplanta-
ti on, hearkening back to the earl y days of hemodialys is. A s bi oethi cs 
has evolved from darker days in Seattl e, these criteria are much more 
transparent and ev idence-ba ed. ontroversies in organ donation re-
main. such as whether patients o f advanced age or cogniti ve impairment 
are treated fa irly w ith in the sy tem.211 By advocating for patients to sign 
donor cards and express their w ishes to family and fri ends, ensuring that 
all patients who may benefi t from transplantati on are as e sed and added 
to waiting lists. we can pl ay a ro le in ensuring that acce s to hemodialy-
sis remain w ide pread, and open to newly diagnosed pati ents and tho e 
inelig ible for transplant. 
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